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ABSTRACT  
  
Antiretroviral therapy (ART) drugs such as stavudine (d4T) are known to have off-target 
side-effects, including the inhibition of DNA polymerase gamma which replicates 
mitochondrial DNA (mtDNA).  ART-induced depletion of mtDNA copy number may cause 
mitochondrial toxicities such as sensory neuropathy (SN). Genetic variation in DNA 
polymerase gamma or in other nuclear genes influencing mtDNA replication and mtDNA 
copy number may therefore contribute to susceptibility to d4T-induced SN. DNA samples 
from 263 HIV-positive South African adults exposed to d4T were classified as cases with SN 
(n = 143) and controls without SN (n = 120). A total of 28 single nucleotide polymorphism 
(SNPs) were chosen in nuclear genes from the mtDNA replication pathway and from a 
GWAS paper examining SNP association with ART-induced SN (Leger et al. 2014). 
Genotyping was performed using Sequenom Mass Spectrometry. MtDNA copy number was 
determined using a qPCR assay. Associations between SN and genetic variants, between 
genetic variants and mtDNA copy number, and between mtDNA copy number and SN were 
evaluated in univariate and multivariate models using Plink v1.07 and GraphPad v7. Age and 
height were significantly different in the cases with SN vs controls without SN. In univariate 
analyses, three SNPs and two haplotypes were significantly associated with SN, three SNPs 
were associated with pain intensity and three haplotypes were significantly associated with 
mtDNA copy number. However, there were no significant associations with SN, pain 
intensity or mtDNA copy number after correction for multiple SNP testing. No significant 
difference in mtDNA copy number in cases vs. controls was observed. In conclusion 
variation in nuclear-encoded mitochondrial genes examined in the current study do not play a 
role in ART-related mitochondrial complications such as changes in mtDNA copy number, 
or occurrence of SN.  
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CHAPTER 1: INTRODUCTION 
  
2  
  
1.1 HIV epidemic and HAART  
Over the past 30 years, Human Immunodeficiency Virus (HIV) and the resulting 
Acquired Immunodeficiency Syndrome (AIDS) has caused a globally devastating 
pandemic (Streatfield et al., 2014; Singh et al., 2012) with an estimated 1.5 
million deaths in 2013 (Murray et al., 2014). The HIV/AIDS epidemic remains a 
prominent health concern in Africa, particularly in South Africa with an estimated 
population of 5.51 million living with the disease in 2014 and over 170 700 deaths 
in 2014 (Statistics South Africa, 2014). However, since the introduction of 
antiretroviral therapy (ART), a significant decrease in mortality rate has been 
observed (Nolan et al., 2003).  
The first antiretroviral (ARV) drugs to exhibit clinical efficacy for management of 
HIV infection were the nucleoside analogue reverse transcriptase inhibitors 
(NRTIs). The mode of action of NRTIs is to inhibit the HIV reverse transcriptase 
from converting viral RNA to DNA (Stankov et al., 2010; Nolan et al., 2003). The 
NRTI drugs are nucleoside analogues that act as competitive substrates along with 
natural endogenous dNTPs for binding by HIV reverse transcriptase, and cause 
truncation of viral DNA chain elongation when incorporated (Nolan et al., 2003). 
The NRTIs include drugs such as zidovudine (AZT), lamivudine (3TC), stavudine 
(d4T), didanosine (ddI), abacavir (ABC), tenofovir (TDF) and emtricitabine 
(FTC).  In 1996, highly active antiretroviral therapy (HAART) was established 
(Lehman and Hoke, 2010). HAART consists of a combination of three or more 
antiretroviral drugs (Lehman and Hoke, 2010). HAART programmes ordinarily 
combine two NRTI drugs with drugs of other classes (using different mechanisms) 
such as the non-nucleoside reverse transcriptase inhibitors (NNRTI) or HIV 
protease inhibitors (PI) (Nolan et al., 2003, Bindu and Anusha, 2011). The ability 
of HAART to eradicate the virus is impeded by the presence of cellular and 
anatomical reservoirs of HIV infection (Shen et al., 2008), due to this reason HIV-
positive individuals require a life time use of HAART in order to keep the viral 
load undetectable. In 2015 there were 36.7 million people living with HIV in the 
world and 17 million had access to ART (UNAIDS, 2015).  
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HAART has significantly decreased HIV mortality (Gonzalez-Duarte et al., 2007); 
however, the rise in antiretroviral toxicity burden mediated specifically by NRTI 
therapy may offset these benefits (Nolan et al., 2003). Despite the benefits of ART 
drugs, there are various long term complications associated with their use adverse 
effects accompanying HAART treatment have become increasingly common 
(Apostolova et al., 2011b). In particular, the NRTIs are associated with 
mitochondrial toxicity which results in serious side effects such as peripheral 
neuropathy, lactic acidosis, hepatic steatosis, lipoatrophy and hyperlactemia 
(Table 1.1). Other adverse side effects such as neurological complications, 
dyslipidaemia, insulin resistance, dysglycemia, lipoatrophy, central fat 
accumulation have become evident in 40-60 percent of HIV-positive patients 
exposed to ART, especially d4T (Sinxadi et al., 2013; Wiebe et al., 2011).   
Table 1.1. Adverse effects associated with NRTIs and the reported 
manifestations of mitochondrial toxicity (Apostolova et al., 2011b).  
Drug 
Family 
Side Effects 
 
Reported Manifestations of 
Mitochondrial 
Toxicity 
NRTI Hypersensitivity syndrome (fever, 
myalgia, headache, malaise, insomnia, 
nausea, 
vomiting, symptoms suggestive of 
upper respiratory tract infection, 
anorexia) 
Rash, Pancreatitis, Lactic acidosis 
Hepatotoxicity and hepatic steatosis 
Peripheral neuropathy 
Hyperpigmentation of palms and soles 
or fingers and nails 
Gastrointestinal effects (flatulence, 
nausea, diarrhoea, abdominal 
discomfort) 
Anemia, neutropenia, Myalgia, 
myopathy 
Dyslipidaemia and lipodystrophy 
Inhibition of Pol G 
Depletion of mtDNA 
Reduction of mtDNA-
encoded proteins 
Respiratory chain dysfunction 
Direct inhibition of ETC 
complexes (I, IV) 
Reduction of ATP levels 
ROS production 
Decrease in membrane 
potential 
Impairment of ADP/ATP 
translocase 
Impairment of fatty acid 
oxidation 
  
In South Africa, HAART consists of standardised national ARV regimens, which 
include first, second and third line regimens (Nattrass, 2006; The South African 
Antiretroviral Treatment Guidelines, 2013).  The South African public sector was 
4  
  
allowed access to ART drugs in 2004, and the first-line treatment in 2004 
consisted of the antiretroviral drug stavudine (d4T) together with lamivudine 
(3TC) and an NNRTI either efavirenz (EFV) or nevirapine (NVP) (Nattrass, 2006; 
Orrell et al., 2007). d4T was an affordable and efficacious ART drug and it was 
widely used as part of the first-line treatment of HIV in resource limited settings 
regardless of its detrimental effects on the neuronal cells (Phillips et al., 2010). 
The second-line regimen consisted of lopinavir/ritonavir (LPV/r), AZT and 
didanosine (ddI), and it was offered to patients on whom the first line treatment 
failed (Orrell et al., 2007).  
However due to the high toxicity of d4T, The World Health Organization (WHO) 
has since 2010 recommended the use of TDF instead of stavudine in national 
programs (Brennan et al., 2012). The need for better treatment outcomes through 
reduced toxicity and better ARV drug adherence was the reason for the change 
(Brennan et al., 2012). Currently (i.e. post 2010) the first-line regimen in South 
African guidelines consists of a fixed-dose combination (FDC) that contains 300 
mg TDF, 200 mg FTC or 3TC and 600 mg efavirenz (EFV) (Davies et al., 2013).  
  
1.2 Sensory neuropathy  
Sensory neuropathy (SN), or peripheral neuropathy, is a frequent side effect of 
HIV disease and perturbs the life of patients infected with the virus (Wadley et al., 
2011). SN is a common neurological problem in HIV-positive individuals both on 
and off ART. A painful sensory neuropathy is often developed by about 30% to 
60% of patients harbouring the HIV virus (on and off ART) and it is usually 
characterised by degeneration of both unmyelinated and myelinated nerve fibres in 
a length dependent manner (Kamerman et al., 2012; Keswani et al., 2002). 
Previous studies in South Africa reported that about 60% of HIV-positive 
outpatients receiving ART treatment were diagnosed with SN (Maritz et al., 2010; 
Wadley et al., 2011; Wadley et al., 2014).  
SN experienced in HIV infection comprises of two types that are clinically 
undistinguishable, namely:   
5  
  
• Distal symmetric polyneuropathy (DSP) which develops due to the HIV 
virus itself and is usually a complication of advanced immunosuppression 
by HIV infection (Phillips et al., 2010). Neurons do not express CD4+ 
receptors, thus neuronal damage observed in HIV-positive patients its 
unlikely to have been due to active infection of neurons (Acharjee et al., 
2010), but may arise due to infiltration of activated immune cells into the 
peripheral nerves.   
• Antiretroviral toxic neuropathy (ATN) which results due to toxicity 
induced by exposure to NRTI antiretroviral treatment (Hahn & Husstedt, 
2008). Subsequent to the introduction of ART, an increase in the incidence 
and prevalence of SN has been observed (Wadley et al., 2011). This 
escalation is associated with the use of ART treatment including NRTI 
such as d4T (Wadley et al., 2011).  
SN is a disease that is characterised by damage to distal peripheral nerves (i.e. 
peripheral neuropathy) approximately within the same areas on both sides of the 
body. It typically starts by affecting hands and feet, which may further advance to 
the arms and legs. Degeneration usually affects the distal portions of axons first 
and atrophy of axons progresses gradually in the direction of the nerve cell body 
(Hughes, 2002). Pain is the most common feature of SN, and it is usually bilateral, 
of slow onset and often described as “painful numbness, aching, or burning 
sensation” (Hao, 2013). Other signs and symptoms include a sense of pins and-
needles, loss/reduced reflexes of ankles and loss of sense of vibration (Wadley et 
al., 2011).  
The most important mediators of SN are the HIV virus, HAART drugs especially 
NRTIs, and the immune response to the HIV virus. These are all, either in 
combination or individually potentially toxic to the nervous tissues (Kamerman et 
al., 2012). An improved understanding of how these three factors bring about the 
clinical phenotype is limited which has resulted in a delay for the development of 
efficacious therapeutic intervention (Maritz et al., 2010).  
6  
  
The histological feature that seems to be common in patients with both DSP and 
ATN is severe loss of dorsal root ganglion (DRG) sensory neurons, DRG 
infiltration by macrophages infected with HIV, degeneration of distal long axons 
and a “dying back” neuropathy (Hao, 2013). Degeneration of axons and the 
reduction of nerve fibre density across the nerve trunk periphery, neuronal loss in 
the DRG and a dying-back of peripheral nerves are characteristics of SN. Nerve 
biopsies obtained from individuals who died due to the advancement of the 
disease, have shown the presence of immune cell infiltration and accumulation of 
inflammatory markers released into DRG and peripheral nerves (Verma and 
Simpson, 2007).   
The use of immunohistochemistry technique reveals macrophage activation within 
the epineurium of peripheral and dorsal nerve ganglia (Verma and Simpson, 
2007). These reactive macrophages in regions of axonal degeneration cause the 
local release of pro-inflammatory neurotoxic cytokines with expression of TNF-
alpha, interleukin IL-1 and IL-6 (Hao, 2013; Wadley et al., 2013). This cytokine 
response is essential for the removal of the pathogen (HIV); but a prolonged or 
large response can result in pathology such as SN (Verma and Simpson, 2007). An 
increase above normal levels of TNF-alpha in HIV-1 positive individuals might 
also lead to extra neurodegeneration (Hao, 2013).  
A better understanding of the pathogenesis of SN is needed in order to better 
understand and identify predisposing factors which will aid in the implementation 
of effective preventative and pain management strategies (Phillips et al., 2010).  
 1.3 Mitochondrial toxicity of ART (POLG hypothesis)  
In healthy individuals, mammalian somatic cells contain up to several thousand 
mitochondria, with each mitochondrion containing 1–10 copies of mitochondrial 
DNA (mtDNA) (Cummins, 1998). Therefore, normal human cells contain ~1 000 
to 10 000 copies of their mtDNA genome per cell. This is not a fixed number and 
the tissues’ energy demand has a regulatory effect on mtDNA copy number (Lee 
& Wei, 2005, Shen et al., 2008). mtDNA copy number can be described as an 
absolute number, or can be described in comparison to the amount of nuclear 
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DNA (nDNA) present i.e. the mtDNA:nDNA ratio or relative mtDNA copy 
number.  
It has been shown that HIV infection decreases mtDNA copy number. A study by 
Côté   et al.  (2002) indicated that HIV infected patients (ART-naïve) had reduced 
levels of mtDNA compared to HIV-negative and age matched patients used as 
controls. HIV-positive patients were found to have approximately 34% reduction 
in mtDNA: nDNA ratio as compared with HIV-negative controls in peripheral 
blood mononuclear cells (PBMC). HIV infection is able to impede the normal 
physiological function of the mitochondria in lymphocytes, inducing mtDNA loss. 
 
ARV use can further decrease mtDNA copy number (refs).   In Cote et al. (2002), 
patients in receipt of d4T-containing ART who developed symptomatic lactic 
acidemia had even further reduced level of mtDNA: nDNA ratio (68% of levels in 
HIV-negative controls) even lower than in the ART-naïve HIV-positive cohort 
(Côté et al. 2002). There was a significant increase in mtDNA levels once ART 
was stopped (Figure 1.1).    
  
Figure 1.1. Average mtDNA: nDNA ratios in peripheral blood samples 
obtained from different groups of HIV-infected patients. (Côté et al., (2002);  
http://depts.washington.edu/hivaids/arvae/case5/discussion.html).  
 
de Mendoza et al., (2004) also indicated that d4T induced mtDNA depletion in 
PBMC from HIV-positive patients on ART as compared to HIV-positive 
treatment naïve and HIV-negative individuals (Figure 1.2).  de Mendoza et al., 
8  
  
(2004) concluded that HIV on its own and together with d4T treatment can induce 
mtDNA copy number loss in PBMCs but other types of HAART were not as 
toxic. These results were similar to those in a clinical trial by Gallant et al. (2004), 
whereby TDF was compared with d4T and TDF was found to be less toxic (in 
vitro) to the mitochondria than d4T.   
  
Figure 1.2.  mtDNA copy number in HIV-negative patients vs. HIV-positive 
patients who were either drug-naïve or using d4T or other ART (from de 
Mendoza et al., 2004). 
  
Menezes et al. (2013) investigated the early effects of d4T in comparison with 
TDF on mtDNA copy number in adipose tissue in black South African patients. 
The study cohort (n = 60) consisted of HIV-positive patients taking varying doses 
of d4T or TDF based ART. The patients who were exposed to the standard and 
low dose d4T had a decrease in mean mtDNA copy number/cell of 29 % and 32 
%, respectively when compared with TDF after only four weeks.    
  
The mechanism by which NRTIs decrease mtDNA copy number is thought to be 
via the “POLG hypothesis” (Brinkman 1999). NRTIs inhibit the reverse 
transcriptase enzyme of HIV by competing with endogenous nucleic acids for 
incorporation into nascent DNA. By the same mechanism, NRTIs also inhibit 
human DNA polymerase gamma (POLG) which is responsible for the replication 
of mtDNA.  While there are several types of human DNA polymerase, mtDNA 
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POLG appears particularly susceptible to inhibition by NRTI, as it lacks the 
ability shared by nDNA polymerases to effectively discriminate against NRTI in 
favour of endogenous nucleic acids (Nolan et al., 2003). NRTI inhibition of 
POLG leads to premature mtDNA termination, decreased mtDNA replication and 
decreased mtDNA copy number. In addition, the inhibition of POLG 
exonucleolytic proof reading capacity introduces errors during replication of 
mtDNA, and the usual mtDNA repair mechanism becomes less effective due to 
NRTIs ability to resist exonucleolytic removal (Lewis et al., 2006; Brinkman et 
al., 1998; Apostolova et al., 2011a).  
  
There are significant differences in the relative potencies of NRTI in their ability 
to interact with POLG and change mtDNA copy number. In particular, the NRTI 
“D–drugs” such as d4T, ddc, 3TC and ddl in their triphosphate state are more 
easily incorporated in the elongated strand of mtDNA in vitro than NRTIs such as 
ABC, TDF and AZT (Birkus et al., 2002), therefore cause particularly lowered 
levels of mtDNA. The hierarchy of gamma-polymerase inhibition for the active 
NRTI metabolites has been determined as follows: zalcitabine (ddC,) > didanosine 
(ddI), > stavudine (d4T) > lamivudine (3TC) ≥ abacavir (ABC) ≥ tenofovir (TDF) 
≥ emtricitabine (FTC)” (Birkus et al., 2002, Figure 1.3). 
  
Figure 1.3. Depletion of mtDNA in skeletal muscle cells  is particularly 
associated with D drug-NRTIs (d4T, ddC and ddI)  (Birkus et al., 
2002)(http://www.medscape.org/viewarticle/466101).  
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1.4 Mitochondrial DNA copy number and ART side-effects  
D-drug-dependent inhibition of mtDNA gamma polymerase and reduction in 
neuronal mitochondrial DNA copy number is thought to be the cause of SN in 
HIV infected individuals. NRTI use leads to reduced mtDNA copy number via 
inhibition of mtDNA synthesis.  The enzyme polymerase gamma is inhibited by 
NRTI (Figure 1.4) which blocks replication of mtDNA, thus producing less 
adenosine triphosphate (ATP) and producing more reactive oxygen species (ROS) 
which damages the integrity of the mitochondrion and mtDNA (Hao, 2013). In a 
second mechanism, NRTIs are also thought to be able to act as stimuli for release 
of cytokines and chemokines by glia, which further induces neuronal sensitisation 
(Hao, 2013).  
  
  
Figure 1.4. A model of two ways in which NRTIs may induce neuropathic 
pain in HIV patients on ART (modified from Hao, 2013).  
Several studies have suggested that changes in mtDNA copy number may be 
linked with occurrence of ART-induced mitochondrial toxicities, including 
sensory neuropathy, lipodystrophy and changes in lactate levels. These are 
summarised below.   
Dalakas et al. (2001) found that ddC use induced mitochondrial DNA loss in 
nerve cells of HIV-positive patients with Peripheral neuropathy. In order to 
understand the cause of the peripheral neuropathy, a molecular and morphological 
analysis was performed on nerve biopsy specimens from patients exposed to ddC 
(diagnosed with peripheral neuropathy) and from control subject with only 
peripheral neuropathy but not exposed to ddC. Abnormal and normal 
mitochondria were counted from the nerve cells, and mtDNA copy number 
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detection was conducted using qPCR. Morphological examination of the nerve 
biopsies indicated varying levels of axonal degeneration in all nerves. The ddC 
exposed patients showed severe myelin degeneration and 80% mtDNA copy 
number reduction in nerves as compared to the controls.   
 
Kampira et al. (2014) investigated whether mtDNA depletion in whole blood 
could be used as a biomarker for d4T-induced mitochondrial toxicities in a case 
control study. A total of 203 HIV-positive patients exposed to d4T-containing 
ART from Malawi (n = 43 presented with SN, n = 20 presented with 
lipodystrophy, n = 113 presented with lactic acidosis) were compared to 64 
healthy controls. Their results proved that mtDNA depletion from PBMCs can 
serve as a marker for lactic acidosis due to d4T use; however, did not support the 
use of mtDNA depletion as a marker for SN or lipodystrophy.   
  
Chiappini et al., (2004) found no association between mtDNA copy number and 
lipodystrophy or plasma triglyceride levels after AZT ART use. However, 
Chiappini et al., (2009) explored the relationship between POLG gene SNPs and 
lipodystrophy due to d4T NRTI use. Three POLG SNPs (R1146, E1143 and 
E1146) and CAG repeats of POLG were studied in 69 HIV-positive patients 
treated with d4T and diagnosed with lipodystrophy compared to 138 patients 
without lipodystrophy. The E1143 SNP was significantly associated with both 
lipodystrophy and low mtDNA copy number in PBMCs after d4T ART use.  
  
Many other studies outside the context of ART use have also shown that 
peripheral neuropathy is a common manifestation of mitochondrial disease or 
mitochondrial depletion. Luigetti et al. (2016) studied patients diagnosed with 
mitochondrial diseases such as Mitochondrial neurogastrointestinal 
encephalomyopathy (MNGIE), Mitochondrial encephalomyopathy, lactic acidosis 
and stroke-like episodes (MELAS) and Myoclonic epilepsy with ragged-red fibres 
(MERRF). A total of 100 %, 92 % and 69 % of patients diagnosed with MNGIE, 
MELAS and MERRF presented with peripheral neuropathy, respectively.  
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In summary, several typical side-effects to NRTIs, including sensory neuropathy, 
lactic acidosis and lipodystrophy have been demonstrated to associate with low 
mtDNA copy number. Association between peripheral neuropathy and inherited 
mtDNA depletion syndromes has also been shown.  These have been 
demonstrated in diverse tissues such as adipocytes, neurons, leukocytes and whole 
blood. However, these observations have not been consistently upheld, since some 
studies did not find significant associations between mtDNA depletion after ART 
use, and SN or lipodystrophy (Cherry et al., 2002; Van Oosterhout et al., 2013). 
Hence the use of mtDNA copy number as a marker for ART-induced toxicity 
remains debatable.   
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1.5 Pharmacogenetics of ART-induced sensory neuropathy  
Pharmacogenetics is the study of genetic variants and their role in influencing 
inter-individual variability in responses to a pharmacologic therapy (Ortega & 
Meyers, 2014). Pharmacogenetics epitomizes a gene-environment interaction 
whereby genetic variation interacts with an exposure to the environment (drug) to 
modify a quantifiable phenotype associated to drug effectiveness or toxicity 
(Ortega & Meyers, 2014).  
The fact that not everybody exposed to NRTIs develops SN, suggests that there 
may be an underlying genetic predisposition towards development of SN in 
response to ART use.  Variation in several candidate genes has been suggested to 
modify the predisposition to developing SN (Hendry et al., 2013). The 
pharmacogenetics underlying SN in the samples used in the current study have 
already been studied extensively and the following genes (Table 1.2) have been 
examined so far.   
 
A genome wide association (GWAS) study of peripheral neuropathy with D-drug 
containing regimens in HIV-positive patients was performed by Leger et al., 
(2014).  A total of 254 participants including 90 SN cases and 164 controls 
without SN from the AIDS Clinical Trials Group protocol 384, using d4T or ddl-
containing ART, were studied.  Approximately one million genome-wide SNPs, 
as well as 1 395 selected SNPs in 46 candidate genes associated with peripheral 
neuropathy, were investigated for association with SN. The cohort was made up of 
Black (34%), Hispanic (17%) and Caucasian (49%) individuals. No SNPs were 
consistently found to be associated with new onset peripheral neuropathy at 
genome wide significance. Susceptibility to d4T/ddI-associated neuropathy was 
not explained by a single genetic variant with a marked effect.  
However, the following SNPs CCDC19 rs2501325, LITAF rs13333308, ZNF648 
rs7554182, NFE2L3 (NRF3) rs4722585 from Leger et al. (2014) were chosen for 
replication in our study due to their low P-values and high association odds ratio 
(OR) with peripheral neuropathy at genome wide level.  ZNF648 rs7554182 had 
the lowest GWAS P-value (P = 5.7 x 10-08, OR = 48.5) in Black individuals with 
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grade 3 SN only, defined as sensory alteration or paraesthesia causing inability to 
perform usual social and functional activities. NFE2L3 (NRF3) rs4722585 had the 
lowest GWAS P-value (P = 4.4 x 10-06, OR = 0.2) in Black individuals, in 
association with grade 2 SN in Leger et al. (2014), where grade 2 was defined as 
sensory alteration or paraesthesia causing greater than minimal interference with 
usual social and functional activities. CCDC19 SNP rs2501325 and LITAF SNP 
rs13333308 had lowest P-values (P = 1.3 x10-03, OR = 0.2 and P = 6.0 x 10-06, OR 
= 32.3) in analysis using 46 candidate genes only in Blacks with grade 2 and grade 
3 SN respectively. Leger et al., (2014) suggested that these results be replicated in 
other cohorts of HIV-positive patients diagnosed with SN.      
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Table 1.2. Genes already examined in association with SN in various cohorts.  
Examined 
Genes  
Cohort(s)  Reference(s)  Phenotype 
examined  
Study 
conclusions  
POLG Malawians, 
French 
Van Oosterhout 
Chiappini 
 
Peripheral 
Neuropathy, 
Lipodystrophy, 
mtDNA copy 
number 
 
 
None 
Significant 
MHC III (BAT  
& TNFA)  
  
Africans, 
Chinese, 
Indonesians, 
Malaysians & 
Caucasians.  
South Africans  
(current study 
cohort)  
(Cherry et al., 2008), 
(Chew et al., 2011), 
(Affandi et al., 2008)  
(Wadley et al., 2014)  
Lipodystrophy,  
Pain Intensity, 
Peripheral 
Neuropathy  
 
 
 
Significant 
Association 
Cytokine s 
 
Africans & 
Europeans  
(Cherry et al., 2008)  Pain Intensity 
Peripheral  
Neuropathy  
and  
 
Significant 
Association 
Cytokines  Southern 
Africans 
Wadley et al., 2013 Sensory 
Neuropathy, 
Pain Intensity 
Significant 
Association 
Mitochondrial 
uncoupling  
Proteins  
(UCP)  
South Africans  
(current study 
cohort)   
(Wadley et al., 2013)  Pain Intensity  
Peripheral  
Neuropathy  
and  
 
None 
Significant 
GTP  
cyclohydrolase 
1 (GCH1)  
South Africans  
(current study 
cohort)  
& Europeans  
(Wadley et al., 2012)  Pain Intensity  
Peripheral  
Neuropathy  
and  
 
None 
Significant 
KCSN1  South Africans  
(current study 
cohort)  
(Hendry et al., 2013)  Pain Intensity  Significant 
Association 
mtDNA  
haplogroups  
Africans (Black  
Malawians)  
South Africans  
(current study 
cohort)  
(Kampira  et  al.,  
2013);   
(Goldfein, 2014)  
Lactic Acidosis 
and  
Peripheral  
Neuropathy;  
CD4 count   
 
None 
Significant 
GWAS Americans 
(Blacks, 
Hispanic, and 
Caucasians) 
Leger et al., 2014 Sensory 
Neuropathy 
None 
significant 
at genome-
wide level 
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1.6 Genetics of mitochondrial DNA copy number  
In the current pharmacogenetic study, we have chosen to study mtDNA copy 
number and genetic variation in nuclear genes which influence mtDNA copy 
number. Variation in genes controlling mtDNA copy number may influence 
susceptibility to NRTI-induced mtDNA copy number- mediated side effects. Host 
genetic variation of the mtDNA and/or nuclear-encoded mtDNA genes may play a 
vital role in determining the degree of d4T toxicity (Sinxadi et al., 2013) and 
mtDNA depletion (Zhang & Singh, 2014). Genes that regulate mitochondrial copy 
number may harbour genetic variation that may cause an underlying susceptibility 
to mtDNA copy number depletion that is not phenotypically noticeable until 
NRTIs are used. There is a concept of a threshold level of mtDNA depletion 
before symptoms are noticeable.  The mtDNA copy number may be lowered to a 
subclinical level due to inherited genetic mutations in genes controlling mtDNA 
copy number, which then get further lowered past the threshold point by ART, 
causing symptoms (Montier et al., 2009).  
Yamanaka et al. (2007) and Bailey et al. (2009) suggested that NRTI treatment in 
the context of POLG mutation may reduce mitochondrial function below clinical 
threshold, causing mitochondrial disease. A common SNP in POLG is E1143G 
found in about 4% of the general population and associated with functional 
impairment of POLG (Copeland, 2010). Hudson et al. (2006) observed that 
functional genetic variants of POLG are present in up to 0.5% of the general 
population. It is possible that there are genetic polymorphisms present at 
reasonable frequency in South African populations within POLG or other 
candidate genes that may make them more susceptible to the effects of d4T.  
POLG, the gene encoding polymerase gamma enzyme has been the major nuclear 
gene that has previously been studied in ART-induced SN and ART-induced 
changes in copy number. Mutations in POLG have been comprehensively studied 
for their role in mitochondrial copy number disorders (Ponamarev et al., 2002. 
Van Goethem et al., 2001. Longley et al., 2005).  The National Institute of 
Environmental Health Sciences (NIEHS) has developed a POLG database that 
catalogues more than 120 POLG mutations and their associated disorders 
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(http://tools.niehs.nih.gov/polg/). Yamanaka et al. (2007) reported that a novel 
homozygous DNA POLG mutation (R964C) was associated with increased 
mitochondrial toxicity from NRTI treatment in a Japanese woman with 
HIV/AIDS. Yamanaka et al (2007) using cell lines treated with NRTI d4T, found 
that cells harbouring the POLG mutant R964C had considerably decreased 
mtDNA levels as compared to the wild type POLG. In patients diagnosed with 
d4T induced lipodystrophy the E1143G mutation was significantly associated with 
reduced mtDNA content (Chiappini et al., 2009). Chen et al., (2002) found no 
association between POLG CAG repeat length in the second exon and lactic 
acidosis or neuropathy in HIV-positive Dutch patients exposed to ART. In a 
cohort study of HIV-positive patients from Malawi treated with d4T containing 
ART and experiencing severe d4T induced side effects, POLG was sequenced, but 
it was found that no mutations were harboured by the patients (Van Oosterhout et 
al., 2013; Kampira et al., 2013). This might suggest that monogenic POLG 
mutations are not a common pathogenic determinant of severe d4T-associated 
mitochondrial toxicity in Malawians (Van Oosterhout et al., 2013; Kampira, 
2013). 
To identify genetic variation in other nuclear genes apart from POLG which 
influence mtDNA copy number, an understanding of mtDNA replication is 
required. A brief description of mtDNA replication and the genes involved 
follows, with a suggestion of candidate genes to be considered in this study.  
The mitochondria are cellular organelles that are ubiquitous in eukaryotes and are 
sites of vital cellular functions (Montier et al., 2009) such as programmed cell 
death, cellular proliferation, signal transduction (Zhang and Singh, 2014), 
synthesis of key catalytic subunits of the electron transport chain complexes and 
synthesis of ATP (Suomalainen and Isohanni, 2010). The primary function of the 
mitochondria is the production of ATP molecules through the process of oxidative 
phosphorylation, which serves as energy for cellular functions (Montier et al., 
2009).  
Human mitochondria contain numerous copies of double stranded haploid DNA of 
approximately 16 kb circular genome which encodes 13 proteins responsible for 
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proper functioning of electron transport chain, as well as 22 tRNAs and 2 rRNAs 
needed for the translation of the encoded proteins within the mitochondria 
(Scarpulla, 2008). The 37 mitochondrial genes are encoded by both of the two 
strands of the double stranded DNA designated heavy and light (Arnold et al., 
2012). Human mitochondria also contain a displacement loop (D-loop) or control 
region which is the main non-coding region of human mtDNA and it includes 
promoters which instigate transcription (Arnold et al., 2012). Heavy and light 
strands contain two heavy-strand promoters and one light-strand promoter 
respectively (Falkenberg et al., 2007).  
 mtDNA replication is accomplished by proteins encoded by genes from the 
nuclear genome (Zhang and Singh, 2014; Montier et al., 2009), these proteins 
translocate to the mitochondria. Unlike nDNA replication which is dependent on 
cell division, mtDNA replication is independent of the cell cycle (Hudson and 
Chinnery, 2006). Mitochondrial replication is specifically suited to make as many 
mitochondria as that particular cell needs at the time. There are two suggested 
models of mtDNA replication, namely, the simultaneous and the asynchronous 
model (Carling et al., 2011). Both models have delayed synthesis of the DNA-
lagging strand.  
 Replication and transcription of mtDNA require RNA primers. The RNA primer 
needed for first strand mtDNA replication is synthesised by the mitochondrial 
RNA polymerase (POLRMT) with the assistance of mitochondrial transcription 
factors A, B1 and B2 (TFAM, TFB1M and TFB2M respectively) (Chang and 
Clayton 1985; Fish et al., 2004). TFAM is a key regulator in the activation of 
replication and transcription of mtDNA which bends mitochondrial promoter 
DNA to aid transcription of the mitochondrial genome. TFAM expression is 
influenced by other transcription factors such as nuclear respiratory factor 1 
(NRF1), nuclear respiratory factor 2 (NRF2) and peroxisome proliferator-
activated receptor co-activator 1 alpha (PGC-1a). PGC-1a is another key element 
regulating mitochondrial biogenesis. PGC-1a is also known to activate the 
expression of NRF1 and sometimes NRF2 (Austin & St-Pierre, 2012).   
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NRF2 is a transcription factor that regulates the expression of antioxidant genes by 
binding to their promoter NRF2-antioxidant response element (ARE) (Shimoyama 
et al., 2014).  NRF2 is a key regulator of several pathways including 
mitochondrial biogenesis, mtDNA replication and maintenance, oxidative stress 
(Nagiah et al., 2015).  Both HIV and ARTs increase oxidative stress (Reddy et al., 
2012, Nagiah et al., 2015) which may increase NRF2 expression (Reddy et al., 
2012). Proteins involved in mtDNA transcription that also help to initiate DNA 
replication are summarised in Table 1.3 below.  
Table 1.3. Proteins involved in mtDNA transcription that also help to initiate  
DNA replication  
Protein  Gene  Chromosome  Function  
Mitochondrial 
RNA  
polymerase   POLRMT   19  
Synthesizes RNA primers for 
initiation of replication of the 
mitochondrial genome.  
Mitochondrial 
transcription 
factor A  
(mtTFA)   TFAM   10  
Key activator of mitochondrial 
transcription and participant in 
mitochondrial genome replication   
Transcription 
factor B1   TFB1   6  Transcription Factor  
Transcription 
factor B2  
 TFB2   1  Transcription Factor  
Rnase MRP  RMRP  9  
Initiates mitochondrial DNA 
replication  
Endonuclease G   ENDOG   9  
Modifies  the RNA primers for 
mtDNA replication  
Rnase HI   RNASEH1   2  
 Degrades the RNA primer 
hybridized to mtDNA.  
Nuclear 
respiratory 
factor-1    NRF1   7  
Transcription factor that binds to 
promoters of TFAM and POLG.  
Nuclear 
respiratory 
factor-2   NRF2   2  
 Transcription factor that binds to 
promoters of TFAM and POLG.    
PGC-1a  PPARGC1A   4  
Transcription factor that binds to 
promoters of NRF1 and NRF2.    
Regulator of mitochondrial 
biogenesis and function.  
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Once initiated by the POLRMT complex, mtDNA replication is performed by the 
set of proteins, shown in Table 1.4 and Figure 1.5. The enzyme POLG consists of 
one catalytic subunit which adds dNTPs to the newly synthesised DNA strand 
(p155) and two subunits that ensures high processivity of the catalytic subunit 
(p55) (Carling et al., 2011).  The subunits of the POLG enzyme are encoded by 
two genes, POLG and POLG2 respectively. POLG activity is controlled by 
transcription factors NRF1 and NRF2. mtDNA replication is further supported by 
Twinkle helicase (C10orf2) which unwinds short stretches of dsDNA in the 5′ to 
3′ direction.  mtSSBPs (mitochondrial single-stranded binding proteins) protect 
the single-stranded mtDNA (that serves as a template for lagging strand synthesis 
during mtDNA replication) from being digested by nucleases, and also prevent 
premature annealing or secondary structure formation (Dickinson et al., 2013; 
Carling et al., 2011). Mitochondrial topoisomerases and ligase III catalyse the 
transient breaking and re-joining of DNA strands.  
 
Several studies have examined SNPs in the genes governing mtDNA replication in 
relationship to different phenotypes which may occur due to mtDNA depletion. 
For example, SNPs in these genes have been reported in association with 
Parkinson’s disease, Alzheimer’s Disease, Huntington’s Disease, depression, 
cancer and others (see Table 3.5 in the Results section). There are very few studies 
of SNPs directly associated with mtDNA copy number variation in healthy 
individuals, although a few studies have examined SNP role in athletic ability. 
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Figure 1.5: Mitochondrial DNA replication fork (Stumpf and Copeland, 
2011). (https://www.niehs.nih.gov/research/atniehs/labs/gisbl/pi/mdnar/).  
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Table 1.4. Proteins involved in mtDNA replication. The genes listed here were 
the focus of this study.   
 
Protein  Gene  Chromosome  Function  
DNA  
polymerase 
gamma 1  
 POLG   15q25  
mtDNA replication, builds 
new mtDNA nucleotide 
strand  
DNA  
polymerase 
gamma 2  
 POLG2   17q23–24  
Imparts high processivity to 
the catalytic subunit  
Nuclear  
Respiratory  
Factor-2  
NRF2   2  
Transcription factor that binds 
to promoters of TFAM and 
POLG.    
Twinkle  
Helicase  
 C10orf2   10q23.3  Unwinds duplex DNA  
Mitochondrial 
single-stranded 
binding protein 
(mtSSB).  
 SSBP1   7q34  
Prevent premature annealing, 
to protect ssDNA from being 
digested by nucleases.   
Mitochondrial  
Topoisomerase  
1   
 TOP1   10q12-13.1  
Catalyses the transient 
breaking and re-joining of a 
single strand of DNA  
Topoisomerase  
IIIa    
 TOP3a   17p11-11.2  
Controls and alters the 
topologic states of DNA  
Mitochondrial  
Transcription  
Factor A  
 TFAM   10  
Key activator of 
mitochondrial transcription 
and participant in 
mitochondrial genome 
replication  
DNA ligase III   LIG3   17q11.2-12  Ligates the DNA strands  
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Further potential candidate genes influencing mtDNA copy number come from 
studies of mtDNA depletion syndromes (MDS), which are a group of disorders 
inherited in an autosomal recessive pattern, that have severe decrease in mtDNA 
copy number in affected tissues and organs (El Hattab, 2013). Mutations in 
nuclear genes involved in pathways responsible for mtDNA maintenance, 
mitochondrial (dNTP) synthesis and mtDNA replication (such as the genes shown 
in the Tables above) can cause MDS. Genetic variants in proteins involved in the 
synthesis or regulation of mtDNA replication and dNTP pools have been 
associated with severe reduction in mtDNA copy number, which if reduced below 
30% of normal mtDNA content will result in severe and often lethal diseases 
(Cohen & Naviaux, 2010; Rötig and Poulton, 2009). Specifically, mutations in 
POLG, C10orf2, MTSSB, TFAM, dGK, RRM2B, SUCLA2, TK2, and TYMP are 
known to cause mtDNA depletion syndromes (Cohen & Naviaux, 2010).  
 
 PINK1 (PTEN Induced Putative Kinase 1) is another interesting gene that may 
influence mitochondrial copy number. Whilst it is not directly involved in mtDNA 
transcription or replication, it plays a role in mitochondrial quality control, 
targeting destruction of dysfunctional depolarized mitochondria. The PINK1 gene 
encodes for a protein kinase enzyme that localises to mitochondria (Gegg et al., 
2009). This enzyme targets faulty mitochondria for destruction since they lack 
sufficient membrane potential to allow translocation of PINK1 protein into the 
mitochondria, this will lead to excessive accumulation of the protein in the outer 
membrane. Mutations in PINK1 gene are associated with Parkinson’s Disease 
(PD), and mitochondrial involvement in the pathogenesis has also been observed. 
Silencing of PINK1 is associated with mtDNA depletion (Gegg et al., 2009).  
 
In summary, we considered genes that play a role in mtDNA replication and/or 
transcription, and/or in mtDNA depletion syndromes, as candidate genes that may 
regulate mtDNA copy number and development of SN in response to d4T use.  
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AIMS AND OBJECTIVES 
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1.7 Hypotheses and Aims  
 
In this study I examined variation in selected genes chosen from the Leger et al., 
(2014) GWAS paper, as well as selected genes that maintain mtDNA integrity and 
replication.  I hypothesized that: 
1. Variation in candidate genes may associate with occurrence of SN after d4T-
ART use  
2. Variation in candidate genes may associate with pain intensity during 
occurrence of SN after d4T-ART use  
3. Variation in candidate genes may associate with mtDNA copy number in 
patients using d4T-ART 
4. Changes in mtDNA copy number may associate with occurrence of SN after 
d4T-ART use 
 
The aims of this study were therefore to determine the associations between 
genetic variation in candidate nuclear genes, mtDNA copy number, occurrence of 
SN, and degree of pain intensity, in a Black South African cohort using d4T-ART. 
Given the d4T exposure, genotype-phenotype and phenotype-phenotype 
associations will be studied as shown in the following Figure 1.6.  
 
Figure 1.6. Genotype/phenotype associations and phenotype/phenotype 
associations (blue arrows) that will be examined in this study.  
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1.8 Objectives  
 
1. To select approximately 30 candidate SNPs in nuclear genes that may 
influence mtDNA copy number, including genes driving mtDNA 
replication, and SNPs of interest from Leger et al., (2014) paper.  
 
2. To genotype candidate SNPs using MassArray technology, in a Black 
South African case-control cohort with and without SN after d4T use.  
 
3. To examine statistical associations between candidate SNPs and SN 
phenotype in the Black South African case-control cohort, and to examine 
statistical associations between candidate SNPs and pain intensity in SN in 
the cohort.   
 
4. To validate a qPCR assay to measure mtDNA:nDNA ratios (an indicator of 
mtDNA copy number).  
 
5. To use qPCR to measure mtDNA:nDNA ratios in a Black South African 
case-control cohort with and without SN after d4T use.  
 
6. To examine statistical associations between candidate SNPs and mtDNA: 
nDNA ratios in the cohort.  
 
7. To examine statistical associations between mtDNA:nDNA ratios and SN 
in the cohort.  
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CHAPTER 2: MATERIALS AND 
METHODS  
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2.1 Case-control cohort  
  
2.1.1 Sample collection  
The samples used in this research project were obtained from a cohort of Black 
South Africans receiving HIV-treatment at Charlotte Maxeke Academic Hospital 
(Virology Clinic) Johannesburg, South Africa. Blood samples were collected by 
Dr Wadley (Brain Function Research Group, School of Physiology, University of 
the Witwatersrand) between July 2008 and April 2009 as part of her PhD study, 
approved by HREC (Medical), University of the Witwatersrand, protocol no. 
M080220 (Appendix B). The inclusion criteria for participation in the study were 
being HIV-positive, Black Southern Africans, with a minimum age of 18 years or 
older, and having received stavudine-ART for a minimum of six months prior to 
being screened for SN (Hendry et al., 2013; Wadley et al., 2011). Written 
informed consent was obtained from all participants (Wadley et al., 2013).   
Ethical approval for the current genetics study was also obtained from the HREC 
(Medical) University of the Witwatersrand, protocol number M150459 (Appendix 
A). Of the original 342 samples analysed by Wadley et al., (2013), a total of 272 
samples were still available for use in the current study.   
2.1.2 Phenotypic data collection and SN diagnosis  
All participants were assessed by Dr Wadley at the time of blood sample 
collection.  The following demographic and phenotypic data were collected: age, 
sex and ethnicity, height and weight; disease information (current and nadir CD4 
T-cell counts, time since HIV diagnosis and AIDS-defining illnesses); ARV 
treatment history; and other possible causes of neuropathy (diabetes mellitus, 
alcoholism, vitamin B12 deficiency and exposure to isoniazid and chemotherapy) 
(Wadley et al., 2011).   
The patients were screened for sensory neuropathy with the aid of the validated 
AIDS Clinical Trials Group SN screening tool (Cherry et al., 2005).  The 
following subjective symptoms were recorded: pain, aching, burning, numbness 
and a sense of pins-and needles. It was also recorded whether SN symptoms were 
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experienced currently (on day of assessment) or ever (in past but not on day of 
assessment). Objective signs including absent ankle reflex and/or reduced sense of 
vibration were measured by Dr Wadley on the day of assessment. Vibration sense 
was assessed using a 128Hz tuning fork, which was placed on the interphalangeal 
joint of each great toe; vibration sense of ten seconds or less was considered 
abnormal. The combination of at least one (subjective) symptom and at least one 
(objective) sign was indicative of SN presence (Wadley et al., 2011).  Pain 
intensity was documented in patients with pain and was rated on a scale of 0-10.   
2.1.3 DNA isolation  
DNA was extracted from blood samples from the cohort using a salting out 
method (Miller, 1988) by Dr Wadley and stored at -20 °C in nuclease free water 
(Wadley, 2013).  For the current study, stored DNA from the remaining 272 
samples was assessed using a NanoDrop® ND-1000 Spectrophotometer, 
Absorbance values at 260nm and A280nm were measured and DNA concentration 
and quality were calculated.  A total of 263 samples had DNA of acceptable 
quantity and quality (A260:A280 ratio ~1.8) for the current study. The stock DNA 
of all 263 samples was further diluted to a working concentration of 25 ng/μl for 
high throughput genotyping and for mtDNA quantification.   
2.2 mtDNA copy number assessment  
We compared the levels of nuclear to mitochondrial DNA (mtDNA) in human 
DNA samples using quantitative PCR (qPCR). qPCR was conducted with a Light 
Cycler® 480 qPCR instrument (Roche) and SYBR Green chemistry. SYBR® 
Green I (Thermo Fisher Scientific) is an affordable master mix for use as a mode 
of detection of DNA when using qPCR Instrument. SYBR Green is a fluorescent 
intercalating dye which binds to the double stranded DNA (Figure 2.1) and emits 
a fluorescent signal upon binding. In qPCR, DNA accumulates and fluorescent 
signal increases proportionally to the DNA concentration. The excitation and 
emission of maxima SYBR® Green I are at 494 nm and 521 nm, respectively, 
which are compatible with the use on any real-time cycler.  
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Figure 2.1: qPCR quantification of DNA using SYBR Green I for detection 
(Ponchel et al., 2003) (http://www.ngrl-japan.com/gene/gene.html). 
(A) The dye does not bind to ssDNA during denaturation.   
(B) Once annealing is initiated the dye molecules will start binding to the dsDNA.  
(C) During elongation, the dye attached to the dsDNA will emit fluorescence, (D) 
Once the amplicon is fully elongated, the fluorescence intensity will increase 
and will be detected by the qPCR instrument.  
  
“Primer-dimers” or non-specific PCR products also emit fluorescence since they 
are also double stranded DNA. This is a major disadvantage of the SYBR Green 
chemistry and this can give false positives of the results. The primer-dimer issue 
can be avoided when designing primers and by reducing the concentration used. In 
addition, specificity of the PCR reaction must be confirmed as non-specific PCR 
products could contribute to SYBR Green fluorescence.  Measuring fluorescence 
of double stranded mtDNA in comparison to fluorescence of double stranded 
nDNA allows the calculation of relative mtDNA copy number.  
2.2.1 PCR Optimisation  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and nicotinamide adenine 
dinucleotide (NADH1/MT-ND1) genes were chosen as representatives of the 
nDNA and mtDNA respectively. GAPDH is known to be present as a single copy 
in the nuclear genome (Atema et al., 2013) and no pseudogenes of NADH1 are 
present in the nuclear genome (Grady et al., 2014).  These genes have been used 
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successfully elsewhere in mtDNA copy number estimation (Côté et al., 2002; 
Rooney et al., 2015). We performed qPCR using DNA and not mRNA, thus a 
single reference gene was deemed sufficient since we were not measuring gene 
expression (Kampira et al., 2014; Grady et al., 2014). We used two sets of PCR 
primers from each of these genes as shown in Table 2.1 and the primer pair with 
highest specificity were chosen for use in the current study.    
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Table 2.1. nDNA & mtDNA qPCR primers and PCR conditions.  
 Genes  Reference   Forward primer  Reverse Primer  Annealing 
temperature  
Amplicon 
Length  
nDNA    
GAPDH  
  
  
Primer Pair 1(Cooray 
et al., 2002)  
5’-TGACAACGAATTTGGCTACA-3’  5’-GGGGTCTACATGGCAACT-3’  55  196 bp  
Primer Pair 2  
(Toyama et al., 2003)  
5’-AAATCAAGTGGGGCGATGCTG-3’  5-‘GCAGAGATGATGACCCTTTTG-3’  60  208 bp  
mtDNA    
NADH1  
  
Primer pair 1 (Psarra 
and Sekeris, 2011)  
  
5-‘ATGGCCAACCTCCTACTCCTCATT-3’  5’-TTATGGCGTCAGCGAAGGGTTGTA-3’  60  154 bp  
Primer pair 2  
(Bonod-Bidaud et al.,  
2001)  
5-‘CTAGCCCCCATCTCAATCATA-3’  5’-GAATGCGGTAGTAGTTAGGAT-3’  55  243 bp  
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Both PCR primer pairs were used during optimisation assays for each gene using 
regular PCR and qPCR. First we optimised the primers and PCR reactions by 
using conventional endpoint PCR and gel electrophoresis. The PCR master mix 
(KapaTaq) from Lasec and its PCR reaction mix (Table 2.2) were used to prepare 
a 20 μl reaction mix. PCR was done initially with MJ Mini™ Thermal Cycler 
(Gradient PCR) from Bio-Rad and thermal cycling conditions shown in Table 
2.3). Annealing temperatures in Table 2.4 were varied during optimisation with 
the standard PCR.   
The amplicons were run on a 1% agarose gel using 1X TBE buffer solution from 
Life Technologies™ for 40 minutes at 80V. Five μl of amplicons was loaded per 
well using 5 μl of 1X loading dye. The loading dye was supplied by Applied 
Biosystems and gel-staining GR-green was supplied by Inqaba Biotec. The gel 
image was captured with the aid of the Gel-Doc visualisation instrument from 
Bio-Rad. The best annealing temperature was chosen for both target and reference 
genes. Then using the same conditions, the primer specificity was tested on a 
qPCR instrument.  
Table 2.2. KapaTaq (20 μl) regular PCR reaction mix.  
Reagent  Volume  
KapaTaq (2X) Master Mix  10.0 µl  
Forward Primer (10 µM)  0.6 µl  
Reverse Primer (10 µM)  0.6 µl  
Template DNA (25 ng/µl)  3.4 µl  
Water, Nuclease-Free  5.4 µl  
Total Volume  20 µl  
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Table 2.3. KapaTaq cycling conditions.  
Step  Temperature (ºC)  Duration  Cycles  
Initial denaturation  95  3 Minutes  1  
Denaturation  95  30 Seconds    
  
  
35  
Annealing  Tm -5   30 Seconds  
Extension  72  1 Minute  
Final Extension  72  1 Minute  1  
Hold  4-10  ∞  1  
  
Next the qPCR assay was optimised on a Light Cycler 480 qPCR instrument by 
replicating the conditions used during the endpoint PCR optimisation. SYBR 
Green master mix from Thermo Fisher Scientific was used for detection. Thermal 
cycling conditions in Table 2.5 and the qPCR reaction mix in Table 2.6 were 
used for qPCR optimisation. Standard curves were generated for the calculation of 
PCR reaction efficiency.  Triplicates of the following DNA concentration (i.e. 20 
ng/μl; 2 ng/μl; 0.2 ng/μl and 0.02 ng/μl) were used for the standard curves, plus a 
negative control.  qPCR reaction efficiency was calculated with LightCycler 480 
SW 1.5 software. Melting curves (Table 2.5 for thermal conditions) were also 
generated for measure of primer specificity. Generally, a qPCR efficiency 
between 90 and 110% was considered acceptable (Taylor et al., 2010; Pettengil et 
al., 2012).   
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Table 2.4. Annealing Temperature ranges used for PCR optimisation.  
 Genes  Primer Set  Annealing Temperature 
Ranges (°C)  
Best Annealing 
Temperature (°C)  
Amplicon Length  
nDNA    
GAPDH  
  
1(Cooray et al., 2002)  48-53  50  196 bp  
2 (Toyama et al., 2003)  47-58  57  208 bp  
mtDNA    
NADH1  
  
1 (Psarra and Sekeris, 2011)  
  
48-59  58  154 bp  
2 (Bonod-Bidaud et al., 2001)  45-50  50  243 bp  
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The following qPCR conditions (Table 2.5) and qPCR recipe (Table 2.6) were 
chosen as optimal. White 96-well plates (Bio-Rad) compatible with the Light 
Cycler 480 qPCR instrument were used.  
Table 2.5. Thermal cycling conditions as recommended by the SYBR Green 
master mix protocol.  
Step  Temperature (°C)  Time  Number of Cycles  
Initial Denaturation  95  10 Minutes  1  
Denaturation  95  15 seconds    
40  
Annealing  GAPDH Pair 1 (50) 
NADH1 Pair 1 (58)   
30 seconds  
Extension  72  30 seconds  
Melting Curve  97  1 Minute    
1  40  10 Seconds  
95  Continuous  
Cooling  40  40 Seconds  1  
  
Table 2.6. qPCR recipe utilised in this study for quantification of mtDNA.  
Reagent  Volume  
Maxima SYBR Green (Thermo Fisher)  12.5 µl  
Forward Primer (10 µM)  0.6 µl  
Reverse Primer (10 µM)  0.6 µl  
Template DNA (25 ng/µl)  1 µl  
Water, Nuclease-Free  10.3 µl  
Total Volume  25 µl  
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2.2.2 qPCR assay validation  
We validated our qPCR assay using cell lines depleted of mtDNA. Treatment of 
eukaryotic cells with ethidium bromide (EtBr) depletes endogenous mtDNA while 
nDNA is maintained (Seidel-Rogol and Shadel, 2002). The loss of mtDNA 
extinguishes the oxidative phosphorylation system, after a few days, the cells 
completely devoid of endogenous mtDNA (ρ0 cells) die or need supplementation 
with nutrients to sustain viability (Kukat et al., 2008). Treatment of cells with 
EtBr (50ng/ml) for more than 6 days results in extensive cell death (Seidel-Rogol 
and Shadel, 2002).  
HEK293 cells (Sigma-Aldrich) were seeded in T-75 Corning® cell culture flasks, 
then grown in 80% HyClone™ DMEM medium (Thermo Fisher™), supplemented 
with 10% fetal bovine serum (FBS), 1% Pen-Strept (Penicillin + Streptomycin) and 
1% Glutamine. The cells were cultured at 37 °C in a humidified incubator with 5% 
CO2. Untreated cells were harvested by draining the media from the flask and 
washing the cells with 2 ml of Dulbecco’s Phosphate buffered saline (PBS) 
(Thermo Fisher™).  I then added 2 ml of 1X Trypsin EDTA (Lonza), and 
incubated the flask at 37 °C for two to three minutes; then 1 ml of cells was 
transferred into a new flask. This was done for each harvest time point. DMEM 
medium (Thermo Fisher™), was added into the remaining HEK293 cells to 
deactivate the Trypsin-EDTA.  The harvested cells were stored in a -20°C freezer 
for subsequent DNA extraction. These were considered as the untreated or day 0-
time point for analysis.   
For depletion of mtDNA, cells were treated with EtBr (Inqaba Biotec) at day 3 and 
day 6. Once the cell growth confluency of 30 to 70 % was reached, EtBr treatment 
was performed. The HyClone™ DMEM media was supplemented with 0.25 µl of 
10 mg/ml EtBr (Inqaba Biotec) to a final 50 ng/ml EtBr treatment. HEK293 cells 
were harvested (1 ml into a sterile tube) on days 3 and 6 after treatment (TABLE 
2.2) and stored in -20°C freezer for subsequent DNA extraction.  Experiments 
were performed in duplicate.   
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Table 2.7. Cell culture, treatment and harvest schedule.   
  DAY 0  DAY 3  DAY 6  
Cells Harvested for DNA 
Extraction  
Yes  Yes  Yes  
Treated with (EtBr)  No  Yes  Yes  
  
DNA from HEK293 cells was extracted using InvitrogenTM DNA isolation Kit 
from Life Technologies™ (Thermo Fisher™). This kit precipitates and dehydrates 
protein by salting out (Miller et al., 1988). Protease (125 μl) in nuclear lysis buffer 
was added to the pellet, vortexed for 5 seconds and then incubated on a 65°C heat 
block for 10 minutes and vortexed every 2 to 3 minutes. Then 275 μl of protein 
clearing solution was added to the sample and vortexed for 5 seconds, and 
incubated on ice for 10 minutes. The sample was centrifuged at 12000xg for 5 
minutes, and the supernatant was carefully transferred into a labelled sterile 2 ml 
tube. Ice cold 90% ethanol (500 μl) was added to the new tube containing the DNA 
and the DNA was precipitated by inverting the tube multiple times until a white 
translucent mass was visible. The DNA pellet was centrifuged at 12000xg for 5 
minutes and the supernatant was removed by decanting. Finally, 1 ml 70% ethanol 
was added to the DNA pellet and centrifuged for 2 minutes, after which the ethanol 
was removed. The DNA was dissolved in 150 μl of nuclease free water.  
 
This procedure extracts both nDNA and mtDNA. The purity of the DNA was 
tested using a NanoDrop® ND-1000 Spectrophotometer. The DNA was stored at -
20°C. Prior to use for qPCR the DNA was diluted to 20 ng/µl working 
concentration.  
qPCR assays were run on the extracted DNA using primers in Table 2.1 and 
reaction mix and cycling conditions shown in Tables 2.4 and 2.5.  For each well, 
2.5 μl of 20 ng/μl DNA was used. PCR reactions for the GAPDH and NADH genes 
were performed using DNA samples from each time point (i.e. DNA from Day 0, 3 
and 6) in duplicate. PCR efficiency values obtained during primer optimisation 
were used for fold change calculations.   
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For each sample, Ct values were obtained for each of the genes and were averaged 
across replicate wells.  The fold change in mtDNA:nDNA ratio in treated vs 
untreated samples was calculated manually as E
ΔΔCT 
(Livak and Schmittgen, 
2001), where    
ΔΔCT= [CT (target, untreated)−CT(ref,untreated))−(CT(target,treated)−CT(ref,tre 
ated)]  
  
where:  
CT(target, untreated) = CT value of gene of interest (NADH1) in untreated sample   
CT(ref, untreated) = CT value of control gene (GAPDH) in untreated sample  
CT(target, treated) = CT value of gene of interest (NADH1) in treated sample   
CT(ref, treated) =  CT value of control gene (GAPDH) in treated sample  
E = PCR efficiency   
These results were used to confirm that our qPCR assay could detect the depletion 
of mtDNA induced by EtBr treatment and therefore validate the mtDNA copy 
number assay.  
2.2.3 mtDNA copy number in cohort samples  
qPCR reactions for each gene were run in duplicate in separate wells. For the total 
263 samples, a total of 14 plates were used (i.e. 7 plates for each gene). Within 
each plate four samples of serial dilution (standards) were added. These standards 
were used to generate standard curves in each plate. A positive (calibrator) control 
sample (Day 0 DNA from HEK293 cells) and negative control samples were also 
used to account for any possible contamination, these were also duplicated on 
each plate. Table 2.8 below depicts the plate map utilised in this study.  
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Table 2.8. Template of the 96-well plate map used in this study.  
STD: Standards, 1-42: Sample ID’s, TC: Template Control (calibrator), NTC: No Template Control  
  
qPCR assays were run on the cohort DNA samples using primer set 1 of both 
NADH1 and GAPDH genes, reaction mix and cycling conditions as shown in 
Tables 2.2 and 2.4. For each sample, Ct values were obtained for each of the 
genes and were averaged across replicate wells.   For calculation of mtDNA copy 
number per sample, E
ΔCT 
(Rooney et al., 2015) was used, since we were not 
performing expression levels analysis in the current study.  
  
The following quality control (QC) criteria were applied to the samples during data 
analysis:  
• All samples that had no amplification, either due to low or no DNA in 
respective wells were excluded from analysis.   
• Replicate samples that had a Ct difference of more than 2 were excluded 
from analysis.  
• Samples with average Ct of greater than 30 for GAPDH were excluded 
from analysis.  
  
Plate 1 1 2 3 4 5 6 7 8 9 10 11 12
A STD1 STD2 STD3 STD4 1 2 3 4 5 6 7 8
B STD1 STD2 STD3 STD4 1 2 3 4 5 6 7 8
C 9 10 11 12 13 14 15 16 17 18 19 20
D 9 10 11 12 13 14 15 16 17 18 19 20
E 21 22 23 24 25 26 27 28 29 30 31 32
F 21 22 23 24 25 26 27 28 29 30 31 32
G 33 34 35 36 37 38 39 40 41 42 TC NTC
H 33 34 35 36 37 38 39 40 41 42 TC NTC
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2.3 SNP choice (Bioinformatics analysis)  
A thorough literature search was performed to identify SNPs of interest in the 
candidate genes. SNPs in candidate genes were chosen and prioritised according to 
the following criteria:  
• Firstly, SNPs in candidate genes were chosen based on their reported or 
predicted functional effect or effect on mtDNA copy number and or 
association with SN (from literature review)   
• only SNPs that reached MAF≥5% in African population Luhya Webuye in 
Kenya (LWK) were used   
• It was noted whether SNPs were tag SNPs in African population Luhya 
Webuye in Kenya  
• If SNP assay could be designed successfully in Sequenom software.  
Each of these processes is described in more detail below.  
2.3.1 Literature review of candidate genes   
We used NCBI Pubmed (https://www.ncbi.nlm.nih.gov/pubmed), OMIM 
(https://www.omim.org) and SNPnexus (http://www.snp-nexus.org) to find 
literature where SNPs of interest in these genes had been previously described.  
SNPs of interest were those with:  
• Effects on candidate gene expression  
• Effects of candidate gene function  
• Association with SN or any other neuropathy  
• Association with mtDNA copy number  
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2.3.2 Minor allele frequency (MAF)  
In the absence of genotype information from South African populations, SNPs with 
MAF ≥ 5% were chosen in the Luhya Webuye population in Kenya (LWK) as a 
proxy population. The following bioinformatics tools were used to check SNP 
frequencies in LWK:   
• (NCBI) Variation viewer (http://www.ncbi.nlm.nih.gov/variation/view/)  
• dbSNP (http://www.ncbi.nlm.nih.gov/SNP/)   
• 1000 Genomes (http://browser.1000genomes.org/index.html)  Entire 
Genome Interface for Exploring SNPs (ENGINES)  
(http://spsmart.cesga.es/about.php?dataSet=engines).  
• International Hap Map Project (http://www.hapmap.org)  
  
2.3.3 Predicted functional effect  
We used Ensembl (http://www.ensembl.org/index.html) to confirm functional 
effects of SNPs of interest, since its database is embedded with various 
bioinformatics tools that can perform variant effect prediction (VEP). VEP is a 
powerful toolset for the analysis, annotation, and prioritization of genomic 
variants in coding and non-coding regions.  VEP tools included Sorting Intolerant 
from Tolerant (SIFT) and PolyPhen-2; these scores were used in Ensembl to 
measure the severity of the consequence of the changes to protein coding 
sequences. SIFT scores range from 0.0 (deleterious) to 1.0 (tolerated) and 
PolyPhen-2 scores range from 0.0 (benign/tolerated) to 1.0 (deleterious). 
  
2.3.4 SNP assay in Sequenom  
Not all SNPs can be genotyped and or multiplexed when the MassARRay 
platform is employed. There are some SNPs that are difficult to genotype (e.g. 
repetitive region around the SNP of interest, SNPs that are close together and 
pseudogenes).  The SNPs of interest were uploaded into Assay Design Suite v3.1 
which searched for compatible primers. For every SNP, a forward, reverse and 
extension primer was designed. The program identified optimal primers to avoid 
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multiplexed primer combinations that may inappropriately extend primer 
amplification products from different SNPs.  
    
2.3.5 Tag SNPs  
SNPs chosen from the literature were checked to confirm whether they were tag 
SNPs or not. A tag SNP is a representative of other linked SNPs in a region of 
genome with linkage disequilibrium (LD) and the represented group of SNPs 
create a haplotype. Tag SNPs were only chosen if they tagged more than two other 
SNPs and had a minimum LD of r2 ≥ 0.8 with tagged SNPs. Tag SNPs were 
generated with Ensembl and Hap Map SNP genotype data in the African 
population of Luhya Webuye in Kenya.   
Due to budgetary constraints, full tag SNP panels which would completely cover 
the LD patterns of each gene of interest could not be chosen. However, given the 
choice of several SNPs in a gene of equivalent functional interest, tag SNPs were 
prioritised over non-tag SNPs.   
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2.4 SNP genotyping  
A total of 28 SNPs were genotyped in the cohort of 263 Black South Africans 
receiving HIV treatment. Two PCR multiplexes were sufficient for genotyping of 
all 28 SNPs in this cohort. Table 2.9 below indicates which SNPs were in which 
multiplex.  
Table 2.9. SNPs & their corresponding plex number during genotyping on the 
MassARRay spectrophotometer.  
Gene  SNP ID  Plex #  
PINK  
rs10799655  1  
rs622525  1  
ZFN648  rs7554182  1  
 NRF2  rs1962142  1  
NFE2L3  rs4722585  1  
TOP1mt  
rs7387720  1  
rs724037  1  
rs2450772  1  
 TFAM  
  
rs11006126  1  
rs2306604  1  
rs1049432  1  
rs11006132  1  
 C10orf2  
  
rs17113613  1  
rs3740486  1  
rs11190787  1  
LITAF  rs13333308  1  
POLG2  
  
rs9905016  1  
rs2075551  1  
PINK  rs650616  2  
CCDC19  rs2501325  2  
NRF2  
  
rs35652124  2  
rs2886162  2  
TOP1mt   
  
rs2293925  2  
rs11544484  2  
rs7460159  2  
rs4493919  2  
C10orf2  rs3740485  2  
POLG  rs2856268  2  
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Candidate SNPs in the cohort were genotyped using the Sequenom MassARRay 
by Inqaba Biotech (Pretoria). The Sequenom MassARRay platform employs the 
iPLEX Gold biochemistry (as illustrated by Figure 2.2). For each SNP, the 
designed forward and reverse PCR primers were used to generate a short PCR 
amplicon containing the SNP of interest using the following PCR reaction mix 
and cycling conditions (Tables 2.10 and Table 2.11):   
Table 2.10. Reaction components for PCR of target regions containing SNPs of 
interest 
Component  Amount per PCR reaction (µl)  
Nano-pure Water       0.8  
10× PCR Buffer        0.5   
25 mM MgCl2       0.4  
25 mM dNTP mix       0.1  
0.5 µM Primer Pool       1.0  
Polymerase, 5 U/µl       0.2  
DNA template (25 ng/µl)       2.0  
  
Table 2.11. Thermal cycler conditions for amplification of target regions  
Step  Temperature  Incubation Time  Number of Cycles  
1  94°C  2 minutes  1  
2  94°C  30 seconds    
      56°C        30 seconds        46  
      72°C        60 seconds   
     3       72°C      5 minutes       1  
 4  4°C  ∞       1  
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The unincorporated dNTPs were dephosphorylated by shrimp alkaline 
phosphatase (SAP) at 37°C for 40 minutes, followed by a 5-minute incubation 
period at 85°C to inactivate the enzyme. The samples then underwent another 
round of PCR using single base extension primers and mass-modified ddNTPs. 
The following PCR reaction mix and cycling conditions (Table 2.12 and Table 
2.13) for extension amplification were applied. Upon addition of chain 
terminators, there should be allele-specific differences in mass between extended 
PCR products. This mass difference allows the data analysis software to 
differentiate between SNP alleles as shown by Figure 2.2 
(http://agenabio.com/genetics).   
 
Table 2.12. Reaction components for single base extension reaction.  
Component  Amount per PCR reaction (µl)  
Nano-pure Water       0.6182  
10× iPLEX Buffer Plus       0.2  
iPLEX dNTP Termination mix, 45×       0.2  
Probe Pool (11 µM each)       0.9409  
iPLEX Polymerase, 220×       0.0409  
DNA template (PCR+SAP)       7.0  
  
Table 2.13. Thermal cycling conditions of MassARRay instrument using iPlex 
Gold reaction mix.  
      94°C  
60 Cycles/ ---->     
   
5 Cycles ---  
95°C  
52°C  
80°C  
30s  
5s  
3s  
3s  
   
   72°C  3 min  
     15°C  HOLD  
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These products were then applied to a microchip for Matrix-assisted laser 
desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry whereby a 
laser is used to generate ionized products. The ions accelerate into a tube towards 
the detector. The time of flight of these ionized molecules differ depending on the 
mass of the molecule, which is then measured by the mass spectrometer. The 
alleles were differentiated by their mass variation. The MassARRay analyser can 
detect DNA masses from 4500 to 9000 Daltons (Da) and can also discriminate 
analytes separated by atomic mass of 16 Da which is the smallest detectable 
difference between mass-modified chain terminators. Genotype calls were made in 
real-time during MALDI-TOF analysis.  The cohort samples of 263 were 
genotyped using a total of three 96-well plates for genotyping in two multiplexes. 
The generated data were viewed using the data control software package 
SpectroTYPER™. This software translates the mass of the observed primers into a 
genotype for each reaction that allows the evaluation and management of the 
results which can be exported in Excel format.  
  
Figure 2.2. High throughput SNP genotyping work-flow with MassARRay 
spectrophotometer (Svidnicki et al., 2015).
 
(a) PCR amplification of target of interest 
within the Genome, (b) Excess or unused primers are washed off from the amplicons, (C) 
Chain-terminators (ddNTPs) are added to the PCR reaction mix with amplicons, (d) The 
spectro-chip is loaded onto the MALDI-TOF for allele discrimination according to sizes 
generated by ddNTPs, (e) The TYPER Software is used for genotype calling (Homozygous or 
Heterozygous)
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2.5 Statistical analysis  
Plink v1.07 (Purcell et al., 2007; http://zzz.bwh.harvard.edu/plink), HaploView 
v4.2 (Barrett et al., 2005) and GraphPad Prism v7.0 (www.graphpad.com/scientific-
software/prism/) statistical software were used for data analyses.  
2.5.1 Analysis of association between demographic or clinical data, and SN   
Descriptive statistical analyses were performed using GraphPad Prism v7.0. 
Demographic characteristics were described for continuous and categorical 
variables. Association between continuous data (such as age, months HIV-
positive, months on d4T, CD4 count) and SN were analysed by t-test if parametric 
and by Mann-Whitney or Wilcoxon tests if non-parametric. Association between 
categorical data (such as gender) and SN were analysed by Chi-squared or Fishers 
exact tests P-value < 0.05 was considered significant. Any demographic or clinical 
phenotypes that were significantly associated with SN in this analysis, were used 
as covariates during SNP multivariate analysis as described below.   
2.5.2 Analysis of association between demographic or clinical data, and 
mtDNA copy number  
The associations between demographic variables and mtDNA copy number were 
performed using GraphPad Prism v7.0. In most cases both data sets consisted of 
continuous variables, therefore regression analyses were used. For gender, a 
categorical variable, the association with mtDNA copy number was examined 
using T-test. 
2.5.3 Quality control (QC) of SNP data  
Plink v1.07 (Purcell et al., 2007) was used to analyse SNP data. Files of type *.ped, 
*.map and *..hlist were generated for use in Plink. Data quality was computed and 
the following standard parameters were used as QC limits as discussed in Laurie et 
al. (2010). Whatever data that failed to meet any of the settings listed below were 
excluded for analysis in this cohort.     
Minor Allele Frequency (MAF)   <0.01  
Genotyping Rate (< 85 %)  (--mind 0.15)   
Hardy-Weinberg Equilibrium  < 0.001  
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2.5.4 Analysis of allele, genotype and haplotype frequencies in the whole 
cohort  
After QC, allele and genotype frequencies in the entire cohort were calculated by 
direct observation. Where more than one SNP in a gene had been analysed, 
haplotypes and LD were calculated using Plink v1.07 and HaploView v4.20. 
Haplotypes of 2-3 SNPs were generated by Plink v1.07 using the sliding window 
approach. The LD blocks generated by HaploView used the plink.PED input file, 
and all LD blocks were generated with default settings in HaploView.  
The allele frequencies in this South African cohort were compared to those in other 
African populations using data from 1000 Genomes via Ensembl  
(http://www.ensembl.org/Homo_sapiens/Info/Index).   Data from a total of 120 
individuals were used in each populations of LWK and Yoruba (YRI) 
(https://catalog.coriell.org/1/NHGRI/Collections/1000-GenomesCollections/1000-
Genomes-Project).  The allele frequencies of the SNPs of interest for the two 
African populations (LWK and YRI) were obtained using the 1000 genomes phase 
3 data accessed via Ensembl database and HapMap release 28 accessed via 
Engines-SPSmart database (http://spsmart.cesga.es/about.php?dataSet=engines).  
 
2.5.5 Analysis of SNP associations with phenotypes  
Plink v1.07 was used to look for associations between candidate SNPs and clinical 
phenotypes.   
Phenotypes that were considered included:  
• SN (Where a patient presented with at least one symptom and one sign, as 
defined in Wadley et al., 2013). 
• Pain intensity (was measured on a scale of 0 to 10, with 0 being absence of 
pain and 10 representing extensive pain).  
• mtDNA copy number (ratio of nDNA GAPDH:  mtDNA NADH1)  
 
Both univariate and multivariate analyses were conducted.  The following model 
(Figure 2.3) was adopted from Hendry (2015), which follows Plink’s standard 
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procedure for analysis of SNP data. All the selected SNPs and computed 
haplotypes were individually tested for association with each phenotypes using 
Plink v1.07. All associations that had P < 0.05 during univariate analysis were 
further tested for multivariate analysis which took into account any clinical or 
demographic phenotypes that were significantly associated with SN. In both 
univariate and multivariate analyses, P < 0.05 was considered to be significant.   
  
  
Figure 2.3: Model for analysis of data with the aid of Plink (Hendry, 2015).   
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2.5.5.1 Univariate analysis  
The association of individual SNPs with categorical data such as SN presence or 
pain intensity were analysed using univariate data analysis methods of chi-square 
tests or Fisher’s exact tests. Chi-square tests analysed associations in four models 
of inheritance namely, the allelic model and three genotypic models, including 
codominant, dominant and recessive models. Three different genotypic models of 
inheritance were used as follows: The dominant model assessed having at least 
one minor allele versus not having any minor allele, the recessive model assessed 
having two minor alleles versus having at least one major allele, and the 
codominant model assessed all genotypes separately.  If D is the minor allele and 
d is the major allele, the models were   computed in the following manner (Purcell 
et al., 2007):   
 
Whenever five or less observations were presented in one of the models, Fisher’s 
exact test was employed since chi-square test does not yield accurate results in this 
case. Fisher’s exact test uses a 2 by 2 contingency table. Associations between 
haplotypes and phenotypes using Plink v1.07 (Sliding Window Approach) and 
HaploView v4.20 were also analysed. P < 0.05 was considered to be significant.  
Corrections for analysis of multiple SNPs were performed using the Bonferroni 
method (multiply P values by the number of tests performed or by the number of 
SNPs examined). This is used to reduce the chances of obtaining false-positive 
results (type I errors) when multiple pair wise tests are performed on a single set 
of data. 
Additional empirical P-values (pEMP) were also generated using Plink v1.07, a 
Monte Carlo-based method for assessing significance of case–control association 
studies (http://pngu.mgh.harvard.edu/~purcell/plink/). One hundred thousand 
simulations were performed. Plink generated both uncorrected (EMP1) and 
corrected (EMP2) empirical P-values. The corrected empirical P-value (EMP2) 
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calculates the proportion of permutations in which any of the test statistics 
exceeded that particular observed statistic. It does not assume that the tests are 
independent, but controls the probability of observing at least one false positive 
per experiment and hence is more stringent than the conventional EMP1 P-value. 
In both cases, P-values of <0.05 were taken as significant (Hider et al., 2008).  
 2.5.4.2 Multivariate analysis  
Only the SNPs that were found to be significant during univariate analyses were 
considered for multivariate analyses. Multivariate analysis was performed with 
Plink v1.07 using logistic regression for categorical outcomes or linear regression 
for continuous variables. Logistic regression analysis was employed for SN 
association with all SNPs of interest and haplotypes, since SN was a categorical 
variable. Pain intensity and mtDNA copy number association with all SNPs and 
haplotypes was calculated using linear regression analysis since pain intensity was 
a continuous variable. 
The odds ratio (OR) and Beta values (standardized regression coefficients) 
presented in the results section were shown with respect to the minor allele in the 
sample for individual SNP association analysis. OR > 1 indicates that the minor 
allele increased the risk of development relative to the major allele. OR < 1 
indicates a protective effect of the minor allele relative to the major allele.  Beta 
values are a measure of how strongly each predictor variable influences the 
dependent variable. The beta is measured in units of standard deviation. For 
example, a beta value of 2.5 indicates that a change of one standard deviation in 
the predictor variable will result in a change of 2.5 standard deviations in the 
criterion variable. If a Beta coefficient is positive, then the relationship of this 
variable with the dependent variable is positive; this can also be interpreted as 
presence of minor allele association with an increased risk of developing a clinical 
phenotype. A negative Beta value indicates a negative relationship between 
dependent and independent variables, or a protective effect of the minor allele.     
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2.5.6 Genetic risk score (GRS)  
A genetic risk score is an estimate of the cumulative contribution of genetic 
factors to a specific outcome of interest in an individual that takes into account a 
combination of reported risk alleles (Bailey and Igo, 2016).  Although sometimes 
the GRS may also take into account the reported effect sizes. Effect sizes were not 
used in our calculations. While GRS is often based only on allele scores from 
significant loci, we found few significant loci in this study and therefore decided 
to attempt GRS using both significant (P < 0.05) and borderline significant (P > 
0.05 but < 0.1) candidate loci P-values from univariate analysis.  Each allele for 
each SNP was categorised as a risk allele or non-risk allele for the phenotype of 
interest, based on statistical findings and on literature review of SNP function 
(Table 2.14).   
GRS scores were calculated manually for each individual. The score is simply a 
sum across SNPs of the number of risk alleles (0, 1 or 2) for each individual, 
therefore the minimum GRS score per individual was 0 and the maximum was (28 
loci *2) = 56.   We then analysed association between GRS score and phenotype 
using SNPs with P < 0.1. Chi-squared test, unpaired non-parametric T-test (Mann-
Whitney test) and ordinary one-way ANOVA were used for association of SN, 
pain intensity and mtDNA copy number phenotypes respectively.  
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Table 2.14.  Risk alleles and non-risk alleles of SNPs of interest in this study.  
Gene  SNP  Allele 1 (RISK)  Allele 2  
POLG  rs2856268  C  T  
POLG2  rs9905016  T  C  
rs2075551  C  G  
NRF2  rs35652124  C  T  
rs2886162   A  G  
rs1962142  A  G  
C10orf2  rs17113613 A  G  
rs3740485  C  T  
rs3740486  T  C  
rs11190787  G  T  
TOP1mt  rs2293925 A  G  
rs11544484 T  C  
rs2450772  A  G  
rs7387720  G  A  
rs724037  G  T  
rs7460159  G  A  
rs4493919  A  G  
TFAM  rs2306604  A  G  
rs1049432   T  G  
rs11006132  G  A  
rs11006126  C  T  
PINK  rs10799655  T  C  
rs650616  A  G  
rs622525  A  T  
CCDC19  rs2501325  C  A  
LITAF  rs13333308  C  T  
ZFN648   rs7554182  T  C  
NFE2L3  rs4722585  A  G  
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CHAPTER 3: RESULTS  
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3.1 Association of demographic characteristics with SN  
Of the 263 participants, 54.5 % (n = 143) were clinically diagnosed with SN and 
the 120 individuals not clinically diagnosed with SN served as controls (45.5 % )  
Of those 143 individuals diagnosed with SN, 48.3%      (n =127) reported pain as a 
symptom.  Descriptive statistics for the cohorts used in this study are provided in 
Table 3.1. The demographic and clinical data collected from the patients were 
tested for significance between cases and controls. Age and height were 
significantly different in the cases vs. controls.   
  
Table 3.1. Demographic characteristics of study participants.  
  SN+  
n = 143  
SN-  
n = 120  
P-value  Total Cohort  
n = 263  
  
Age      
 Mean(SD)  
40.5(7.7)  35.86(7.2)  0.0001***  38.4  
Height (cm) 
Mean(SD)  
159.4(8.7)  156.4(7.4)  0.007***  158.05  
CD4 Nadir  
(cells.mm3) Mean  
(SD)  
101.6(68.19)  100(74.63)  0.772  78.8  
Gender (%)  F=77%  
M=23%  
  
F=79% 
M=21%  
0.766  F=78% 
M=22%  
CD4 at Sampling  
Mean cells/mm3 
(SD)  
440.7(199.6)  436.2(231.7)  0.446  426  
Months HIV-
positive  Mean 
(SD)  
55.39(41.15)  51.46(36.8)  0.550  47.8  
Months on d4T 
Mean (SD)  
17.34(25.13)  16.46(26.19)  0.934  16.9  
SD  : Standard Deviation  
N  : Total Samples  
F  : Female  
M  : Male  
***  : Significant P-value  
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None of the demographic data was significantly associated with mtDNA copy 
number in our study cohort as shown by Table 3.2. 
Table 3.2. Association of demographic data with mtDNA copy number.  
Demographic variable  P-value  
Age     0.470  
Height (cm)   0.947  
CD4 Nadir (cells.mm3)  0.409  
Gender (%)  0.251  
CD4 at Sampling (cells.mm3)  0.515  
Months HIV-positive   0.414  
Months on d4T  0.773  
  
    
3.2 Cohort DNA quantification  
DNA had already been extracted and stored at -20°C as several studies had already 
been conducted using these samples. For this study, the DNA was quantified for all 
remaining samples using the NanoDrop ND1000 spectrophotometer. The DNA 
from 263 participants was still acceptable for use with average DNA concentration 
of 594.95 ng/μl and average A260/280 value 1.85 (1.7-2.0).  DNA samples were 
diluted to 20ng/μl aliquots.  
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3.3 qPCR assay  
3.3.1 Conventional PCR and primer optimisation  
 
PCR reactions for the nuclear reference gene (GAPDH) and mitochondrial target 
gene (NADH1) were optimised by trying two sets of primers for each gene. Figure 
3.1 depicts the results for GAPDH primer pair 2, which was found to be non-
specific as shown by the double bands and the lower bands were less than expected 
size of 208 bp. The minimum annealing (Ta) temperature was 47°C and the 
maximum was 58°C.  Primer pair 1 of GAPDH was found to be highly specific 
with a band of the correct size of 196 bp for all the annealing temperatures 
generated by the gradient PCR instrument (Figure 3.2). The Ta ranges were (45-
50) °C. The final Ta chosen was 50°C (Figure 3.2), this temperature was then used 
for the qPCR.   
  
The two NADH1 primer pairs yielded single bands of the correct sizes of 154 bps 
and 243 bps respectively during optimisation (Figure 3.3). The negative control 
was also clear of any contaminants and primer-dimers were visible on the gel 
image. The final primer volume was decreased to 0.6 μl at 10uM concentration 
since it produced no primer dimers.  Primer pair 1 (Ta = 58°C) was chosen for 
further optimisation on the qPCR since it had a smaller amplicon size of 154 bps. 
This also was in correspondence with the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE) which suggests small 
amplicons (Bustin et al., 2009).  
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Figure 3.1: Optimisation results of GAPDH primer set 2. Lane 1 (Molecular 
weight marker), Lane 2-8 (DNA samples) and Lane 9 (Non-template control). The 
minimum annealing (Ta) temperature was 47°C and the maximum was 58°C. 
  
  
Figure 3.2: optimisation results of GAPDH primer 1. The Ta ranges were (45-
50) °C. The final Ta chosen was 50°C (Lane 2), this temperature was then used for 
the qPCR. Lane 1 (Molecular weight marker), Lane 2-9 (DNA samples) and Lane 
10 (Non-template control). 
  
  
 Figure 3.3: Optimisation results of NADH1. (A) Primer pair 2, (B) Primer 
pair 1. Lane 1 (Molecular weight marker), Lane 2-9 (DNA samples) and Lane 10 
(Non-template control). Ta ranges pair 1 (48-59) °C and pair 2 (45-50) °C. 
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3.3.2 qPCR optimisation  
The PCR primers were optimised for qPCR using SYBR Green chemistry for 
detection. Standard and melting curves were generated. Figure 3.4 depicts the 
results obtained.  The standard curves were generated so that we could calculate 
how efficient the PCR reactions were when amplifying the target region. 
Efficiency rate (E%) between 90 and 110% (Bio-rad) or 1.90 to 2.10 values 
(Roche) was considered acceptable (Taylor et al., 2010; Pettengil et al., 2012). 
Both the target and reference genes efficiency (E) was within the recommended 
range as efficiencies of 2.04 and 1.93 were obtained for NADH1 and GAPDH 
primers respectively (in Roche terminology). The efficiencies were both close 
enough to consider the usage of the Livak equation (Livak and Schmittgen, 2001). 
The melting curve analysis further supported the specificity seen with normal PCR 
in Figures 3.2 and 3.3. Only one peak was visible on the melting curves of both 
primer sets thus proving the specificity.  
  
Figure 3.4. qPCR primer optimisation of both target and reference genes. 
(A+C) = standard curves with 2 replicates per sample. (B+D) = melting curves with 
melting temperature (Tm) of 55 °C for GAPDH and 63 °C for NADH1. 
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3.3.3 qPCR assay validation  
Table 3.2 shows the threshold cycle (Ct) values obtained for the target and 
reference genes in the validation samples treated with EtBr. The obtained Ct 
values were computed using the Light Cycler 480 SW 1.5 software. Averages of 
duplicated samples (replicates) were calculated (Table 3.3). The Ct values of the 
target mtDNA gene NADH1 increased from day 0 to day 3, and from day 3 to day 
6, indicating decreasing mtDNA, and the Ct values of the reference nuclear gene 
GAPDH remained fairly constant for all time points. The comparison between the 
target gene Ct values and reference gene Ct values is depicted by Figure 3.5.   
Table 3.3. qPCR threshold cycle (Ct) values obtained using HEK293 cells 
DNA.  
Day Target (NADH1)  Reference (GAPDH)  
Replicate Ct 
Values  
Average Ct  Replicate Ct 
Values  
Average 
Ct  
0 (Untreated)  14.28  16.00  15.14  23.08  23.51  23.3  
3 (Treated with 
EtBr)  
16.82  17.52  17.17  22.89  22.58  22.7  
6 (Treated with  
EtBr)  
19.17  19.87  19.52  22.91  22.87  22.9  
  
 
Figure 3.5. Comparisons of average Ct values of NADH1 & GAPDH genes 
over 6 days.  
    
14 
16 
18 
20 
22 
24 
0 3 6 
Treatment Days 
GAPDH 
NADH2 
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Table 3.4 shows the fold changes of NADH1 from day 0 to day 6, relative to 
GAPDH1. Day 0 served as a reference since the cells on that day they were not 
treated with EtBr. The Livak equation used for calculation of fold change of 
nDNA:mtDNA ratio between EtBr treated and untreated was EΔΔCT.   
The mtDNA:nDNA ratio varied across the respective days. The EtBr was effective 
in inducing mtDNA copy number depletion in HEK293 cells. Day 3 showed a 6-
fold decrease in NADH1 gene compared to day0, while on day 6 the fold change 
increased to 27.67-fold compared to day 0. On Day 6 we also observed extensive 
cell death (the medium in which the cells were cultured was turning cloudy). 
These results supported the expected decrease over time in mtDNA in cells treated 
with EtBr and proved that the qPCR assay was working correctly to detect this.   
Table 3.4. Fold change ratios of NADH1 relative to GAPDH.  
  Days  ΔΔCT  
(GAPDH –NADH)  
EΔΔCT (fold change)   
(Treated compared to 
untreated)  
(0-3)   2.59  6.02  
(3-6)   2.195  4.57  
(0-6)   4.79  27.67  
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3.3.4 qPCR in cohort samples  
Once QC settings to the qPCR results was complete, results from 206 individuals 
remained for further analysis in both target and reference genes (Table 3.5) 
including cases (n = 135) and controls (n = 71).  
Our review of the qPCR results showed that negative controls on each plate had 
CT values of 35 or higher. In most cases, CT values for the NADH1 gene were 
higher than CT values for the GAPDH gene, suggesting that as expected the 
amount of mtDNA exceeded the amount of nDNA.  Table 3.5 shows the mean 
CT, mean ΔCT and mean EΔCT (mtDNA:nDNA ratio) values for the cases and 
controls respectively. No significant difference in EΔCt values (Table 3.5) was 
observed between cases and controls (P >0.05). Figure 3.6 shows mtDNA copy 
number distribution in both cases and controls and no significance was detected 
with P = 0.24.  
The Livak method was employed for the calculation of the fold change ratio of our 
target gene (NADH1) in our target (cases) sample relative to our control cohorts 
by calculating 2ΔΔCT. The fold change was not extensive since there was only 
1.21-fold decrease in mtDNA:nDNA ratio in patients with SN as compared to 
those without SN.   
Table 3.5. Average 2ΔCt fold difference in cases vs controls and exact P-value.   
  SN+  
(n = 135)  
SN-  
(n = 71)  
P-value  
Mean CT for GAPDH  21.19  
  
21.21  
  
-  
Mean CT for NADH   13.99  13.74  -  
Mean ΔCT  7.20  7.47    
Mean 2 ΔCT (SD) 
mtDNA: nDNA ratio   
  
197(159.1)  223.7(156.3)  0.099  
ΔΔCT   
  
0.27  -  
Fold change = 2ΔΔCT   
  
1.21  -  
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Figure 3.6. mtDNA copy number (NADH1 to GAPDH) was not significantly 
different between SN+ cases vs. SN- controls. 
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3.4 SNP selection in genes of interest.  
SNPs in candidate genes were chosen and prioritised according to the criteria 
described in Methods and Materials.  
We identified a total of 28 SNPs of interest to be genotyped (Table 3.6), of which 
24 were from the mtDNA replication pathway, and four were from Leger et al. 
(2014). A total of 24 SNPs had associated functional effects, and four SNPs 
(POLG2 rs2075551, C10orf2 rs11190787, TOP1mt rs7460159 and rs4493919) 
were chosen purely on the basis of being promoter region tag SNPs (no function 
known).   
The following SNP (NRF2 rs6721961) was excluded due to inability to be included 
in the multiplex designed with other SNPs.  
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Table 3.6. List of SNPs chosen for genotyping in this cohort.    
GENE  SNP ID  
(Alternative 
ID)  
Alleles  
  
Minor  
Allele  
(Risk)  
MAF  
LWK  
  
Tag SNP  
(number of other 
SNPs tagged)  
Variant Type  
  
Functional Effect  SIFT /  
PolyPhen-2 
score  
 
References  
POLG  rs2856268  
T (-365) C  
T/C  
  
C  0.19    
Yes (4)  
Regulatory  
region / promoter 
variant  
5’UTR   
Changes recognition site for  
AP1 transcription factor;  
Low POLG Expression;  
Higher POLG mRNA in  
breast cancer;  
Diabetic Polyneuropathy.  
  
  
  
  
-  
Popanda et 
al. 2013   
Spitsina et 
al., 2009   
Malyarchuk 
et al., 2011  
POLG2  rs9905016  C/T  T   0.26  Yes (1)  5’UTR/Upstream 
gene variant  
Increased Transcription of  
TC compared to TT  
Increased risk of oral cancer  
TT associates with lower 
mtDNA levels in oral 
cancer than CT or CC  
  
  
  
 -  
Datta et al., 
2016  
rs2075551  C/G  C  0.28  Yes (1)  5’UTR variant  Unknown  -  ENSEMBL  
NRF2  
rs35652124  
T/C  C  0.11  Yes (4)   Intron Promoter    Reduced binding affinity 
of transcription factor; 
Decreased Parkinson 
disease   
  
 -  
Von Otter et 
al., 2014  
rs2886162  
G/A  A  0.46  Yes (2)  Intron   Low NRF2 mRNA  
eExpression  
  
-  
Hartikainen 
et al., 2012  
rs1962142  
G/A  A  0.06  No  Intron   Low NRF2 protein 
cytoplasmic eExpression;  
Associated with neuropathy 
in diabetes  
  
  
-  
 
Hartikainen 
et al., 2012    
Xu 2016  
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GENE  SNP ID  
(Alternative 
ID)  
Alleles  
  
Minor  
Allele  
(Risk)  
MAF  
LWK  
  
Tag SNP  
(number of other 
SNPs tagged)  
Variant Type  
  
Functional Effect  SIFT /  
PolyPhen-2 
score  
References  
  
  
  
  
  
C10orf2  
rs17113613  
(c.1102G>A)  
G/A  A  0.165  No  Missense (V368, 
p.  
V368Ile)  
Exon 1  
Affects subunit interactions; 
decreases mtDNA,  
Associated with muscle 
weakness   
0.45  
(Tolerated)  
SIFT 
Singh et al.,  
2012; Naimi 
et al.  
2006  
rs3740485  C/T  C  0.45    
Yes (4)  
Splice region 
variant  
Progressive External  
Opthalmoplegia (mtDNA 
copy number)  
-  Singh et al., 
2012  
rs3740486  T/C  T  0.45    
Yes (4)  
Splice region 
variant  
Progressive External  
Opthalmoplegia (mtDNA 
copy number)  
-  Singh et al., 
2012  
rs11190787  G/T  G  0.45  Yes (4)  5’UTR variant  Unknown  -  ENSEMBL  
 
 
 
 
TOP1mt 
rs2293925  
(g.144392368 
G>A)  
G/A  A  0.08  Yes  Missense 
Arg525Trp  
Mitochondrial disorders 
(PEO and Alpers syndrome)  
0  
(Damaging) 
SIFT 
Wang et al., 
2011  
rs11544484  
(g.144406705 
C>T)  
C/T  T  0.49  Yes (4)  Missense  
V256I  
Exon 6  
Mitochondrial disorders 
(PEO and Alpers syndrome)  
1  
(Tolerated)  
SIFT 
Wang et al., 
2011  
rs2450772  
(g.144413416 
G>A)  
G/A  A  0.33  Yes (4)  Missense  
D216D  
Exon 2  
Mitochondrial disorders 
(PEO and Alpers syndrome)  
 -  Wang et al., 
2011  
rs7387720  A/G  G  0.26  Yes (4)  Downstream 
Gene Variant  
Mitochondrial dysfunction 
in patients with Diabetic 
kidney disease.  
 -  Swan et al., 
2015  
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GENE  SNP ID  
(Alternative 
ID)  
Alleles  
  
Minor  
Allele  
(Risk)  
MAF  
LWK  
  
Tag SNP  
(number of other 
SNPs tagged)  
Variant Type  
  
Functional Effect  SIFT /  
PolyPhen-
2 score  
References  
TOP1mt rs724037  T/G  G  0.30  Yes (4)  Intron Variant  Mitochondrial dysfunction in 
patients with Diabetic kidney 
disease.   
 -  Swan et al., 
2015  
rs7460159  A/G  G  0.09  Yes  5 prime UTR 
variant  
Unknown  -  ENSEMBL  
rs4493919  G/A  A  0.24  Yes  5 prime UTR 
variant  
Unknown  -  ENSEMBL  
TFAM  rs2306604  G/A  A  0.15  Yes (2)  Intron Variant  Cryptic Splice Site = 
Truncated Protein.  
mtDNA Depletion in 
Neurodegenerative 
Disorders.  
Association with  
Alzheimer’s Disease and 
Parkinson’s disease   
  
  
  
  
-  
Belin et al.,  
2007  
Gatt et al.,  
2013  
Migliore &  
Coppedè,  
2009  
rs1049432  G/T  T  0.36  Yes (4)   3’UTR variant  Mitochondrial dysfunction in 
patients with HD. Associated 
with  
Huntington’s Disease risk   
  
  
-  
Taherzadeh- 
Fard et al., 
2011  
rs11006132  A/G  G  0.37  Yes (4)  3’UTR variant  Associated with 
Huntington’s Disease risk  
  
 -  
Taherzadeh- 
Fard et al., 
2011  
rs11006126  T/C  C  0.41  No  3’UTR variant  Low mtDNA Copy Number 
in Blood cells.  
 -  Cai et al.,  
2015  
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GENE  SNP ID  
(Alternative 
ID)  
Alleles  
  
Minor  
Allele  
(Risk)  
MAF  
LWK  
  
Tag SNP  
(number of other 
SNPs tagged)  
Variant Type  
  
Functional Effect  SIFT /  
PolyPhen-
2 score  
References  
PINK1  rs10799655  C/T  T  0.33  No  Upstream gene 
variant  
Increased PINK1 mRNA   -  Franks et al., 
2008  
rs650616  G/A  A  0.44  No  Non-coding 
transcript exon 
variant  
Increased PINK1 mRNA   -  Franks et al., 
2008  
rs622525  T/A  A  0.14  No  Intron  Increased PINK1 mRNA  -  Franks et al., 
2008  
CCDC19  rs2501325  A/C  C  0.23  Yes (3)  Intron Variant  Sensory Neuropathy  -  Leger et al., 
2014  
LITAF  rs13333308  T/C  C  0.11  Yes (3)  Intron Variant  Sensory Neuropathy  -  Leger et al., 
2014  
ZNF648   rs7554182  C/T  T  0.27  No  Downstream 
gene variant  
Sensory Neuropathy  -  Leger et al., 
2014  
NFE2L3  rs4722585  G/A  A  0.27  No  Regulatory 
region variant  
Sensory Neuropathy  -  Leger et al., 
2014  
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3.5 Sequenom genotyping results  
Figure 3.7A shows an example of a MassARRay spectrum multiplexing the 
candidate SNPs chosen for genotyping in this study. From this MassARRay 
Spectrum, using the TYPER Software a report was generated which distinguished 
between SNP alleles (homozygous or heterozygous) within each sample 
interrogated. Here SNP rs9905016 from POLG 2 was used as an example.  
  
  
Figure 3.7. High throughput genotyping data from the MassARRay system 
showing results from multiplexed SNPs distributed across the range of 
detectable DNA masses from 4500 to 9000 Da.    
SNP rs9905016 genotypes highlighted in red on the MassARRay spectrum.  
(A) Homozygous for the CC allele with mass of 5330 Da only,  
(B) Homozygous for the T allele with mass of 5410 Da only  
(C) Heterozygous for the CT allele with mass of both 5330 and 5410 Da.  
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The genotyping data from n = 263 and 28 SNPs generated by Sequenom 
MassARRay was filtered using the Plink quality control settings listed in the 
Methods section. The total number of samples was reduced from 263 to 248, due 
to the removal of individuals who exhibited <85 % genotyping rate. Of the total 28 
SNPs, 26 SNPs remained after QC (Table 3.7). The two missing SNPs (TOP1mt 
rs7460159 and rs4493919) failed the Hardy-Weinberg Equilibrium and data 
missingness test, so they were filtered out and were not included.   
Table 3.7. Plink QC data of whole cohort samples.  
  Quality Control (QC)  
Unfiltered Data  Filtered Data  
Total Cohort Samples  263 248  
Cases  143  136  
Controls  120  112  
Males  58  54  
Females  205  194  
Total SNPs  28  26  
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3.6 Allele frequencies in whole cohort vs. other African populations  
Allele frequencies were calculated in our total cohort (Table 3.8). 25 SNPs had  
MAF ≥ 0.05, with MAF ranging from 0.064 to 0.438 in SA cohort. TOP1mt SNP 
rs2293925 had a very low MAF of 0.012.   This is the first report of these SNP 
MAF in a South African cohort.   
APPENDIX C shows the genotype frequencies of all 26 SNPs that passed QC 
settings in the cohort of 248 individuals. In all the controls, Hardy-Weinberg 
Equilibrium (HWE) P-values were above 0.05.  
  
We then compared the SA MAF to those in LWK and YRI populations (from 1000 
genomes data), two African populations that may share common ancestry with 
South African populations. The frequencies vary across all three populations 
regardless of all being located on the African continent.   
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Table 3.8. Distribution of allele frequencies in three African population 
groups, [Kenya (LWK) and Nigeria (YRI)] and South Africans.  
GENE  SNP ID  Minor  
Allele  
  
LWK  
n = 120  
YRI  
n = 120  
SA  
(this study)  
n = 263  
P-value  
MAF  MAF  MAF  
POLG  rs2856268  C 0.17 0.17 0.14 0.799 
POLG2  rs9905016  T 0.26 0.19 0.17 0.256 
rs2075551  C 0.28 0.25 0.20 0.412 
NRF2  rs35652124  C 0.11 0.21 0.18 0.150 
rs2886162   A 0.46 NG 0.44 NA 
rs1962142  A 0.06 0.06 0.06 0.999 
C10orf2  rs17113613  A 0.17 0.10 0.14 0.352 
rs3740485  C 0.45 0.46 0.38 0.461 
rs3740486  T 0.45 0.46 0.38 0.461 
rs11190787  G 0.45 0.46 0.37 0.370 
TOP1mt  rs2293925  A 0.08 0.01 0.01 0.006 
rs11544484  C 0.49 0.43 0.43 0.616 
rs2450772  A 0.33 0.43 0.39 0.342 
rs7387720  G 0.26 0.21 0.21 0.622 
rs724037  G 0.30 0.23 0.20 0.239 
rs7460159  G 0.09 0.02 0.38 0.0001 
rs4493919  A 0.24 0.19 0.19 0.602 
TFAM  rs2306604  A 0.15 0.15 0.21 0.427 
rs1049432   T 0.36 0.32 0.22 0.084 
rs11006132  G 0.37 0.33 0.23 0.089 
rs11006126  C 0.41 0.36 0.31 0.338 
PINK  rs10799655  T 0.33 0.38 0.30 0.481 
rs650616  A 0.44 0.43 0.42 0.960 
rs622525  A 0.14 0.27 0.18 0.060 
CCDC19  rs2501325  C 0.23 0.14 0.14 0.148 
LITAF  rs13333308  C 0.11 0.13 0.10 0.793 
ZNF648   rs7554182  T 0.27 0.24 0.26 0.885 
NFE2L3  rs4722585  A 0.27 0.24 0.26 0.885 
*NG  : Not Genotyped.  
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3.7 Haplotypes and linkage disequilibrium (LD) in cohort  
A total of 26 SNPs in eleven genes were examined in this study. For six of these 
genes, more than one SNP per gene was studied and therefore haplotypes in the 
following genes could be considered: TOP1mt (3 SNPs), C10orf2 (4 SNPs), TFAM 
(4 SNPs), PINK (3 SNPs), NRF2 (3 SNPs) and POLG2 (2 SNPs). In addition, 
some of the genes were on the same chromosome, notably PINK, ZNF648 and 
CCDC19 were all on chromosome 1, and TFAM and C10orf2 were both on 
chromosome 10, so haplotypes across these genes could also be examined.  
3.7.1 Haplotype frequencies in cohort  
Haplotype frequencies were generated with Plink v1.07 software using the sliding 
window approach.  All possible three SNP haplotypes on each chromosome were 
generated using the 26 SNPs dataset. A total of 11 possible 3-locus combinations 
(windows) were computed along with their frequencies in the cohort samples 
(Table 3.9). There were eleven 3-locus combinations (windows) that were 
considered but many more possible haplotypes than 11 because each 3-locus 
combination considered can have several different haplotypes. So, a total of 62 
possible haplotypes were generated. 
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Table 3.9. Frequencies of 3 SNP haplotypes in whole cohort.   
LOCUS  CHROMOSOME  GENE  SNPs  HAPLOTYPE  FREQUENCY  
WIN1  1  PINK  rs10799655|rs650616|rs622525  TGA  0.173  
WIN1  1  PINK  rs10799655|rs650616|rs622525  CAT  0.422  
WIN1  1  PINK  rs10799655|rs650616|rs622525  TGT  0.124  
WIN1  1  PINK  rs10799655|rs650616|rs622525  CGT  0.277  
WIN2  1  PINK – CCDC19  rs650616|rs622525|rs2501325  GAC  0.010  
WIN2  1  PINK – CCDC19  rs650616|rs622525|rs2501325  ATC  0.052  
WIN2  1  PINK – CCDC19  rs650616|rs622525|rs2501325  GTC  0.073  
WIN2  1  PINK – CCDC19  rs650616|rs622525|rs2501325  GAA  0.167  
WIN2  1  PINK – CCDC19  rs650616|rs622525|rs2501325  ATA  0.370  
WIN2  1  PINK – CCDC19  rs650616|rs622525|rs2501325  GTA  0.328  
WIN3  1  PINK – CCDC19-ZFN  rs622525|rs2501325|rs7554182  TCT  0.025  
WIN3  1  PINK – CCDC19-ZFN  rs622525|rs2501325|rs7554182  AAT  0.040  
WIN3  1  PINK – CCDC19-ZFN  rs622525|rs2501325|rs7554182  TAT  0.180  
WIN3  1  PINK – CCDC19-ZFN  rs622525|rs2501325|rs7554182  TCC  0.101  
WIN3  1  PINK – CCDC19-ZFN  rs622525|rs2501325|rs7554182  AAC  0.129  
WIN3  1  PINK – CCDC19-ZFN  rs622525|rs2501325|rs7554182  TAC  0.517  
WIN4  2  NRF2  rs1962142|rs35652124|rs2886162  ATA  0.053  
WIN4  2  NRF2  rs1962142|rs35652124|rs2886162  GTA  0.384  
WIN4  2  NRF2  rs1962142|rs35652124|rs2886162  GCG  0.178  
WIN4  2  NRF2  rs1962142|rs35652124|rs2886162  GTG  0.373  
WIN6  8  TOP1mt  rs7387720|rs2293925|rs724037  GAG  0.011  
WIN6  8  TOP1mt  rs7387720|rs2293925|rs724037  GGG  0.181  
WIN6  8  TOP1mt  rs7387720|rs2293925|rs724037  AGG  0.017  
WIN6  8  TOP1mt  rs7387720|rs2293925|rs724037  GGT  0.019  
WIN6  8  TOP1mt  rs7387720|rs2293925|rs724037  AGT  0.772  
WIN7  8  TOP1mt  rs2293925|rs724037|rs11544484  AGC  0.012  
WIN7  8  TOP1mt  rs2293925|rs724037|rs11544484  GGC  0.191  
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LOCUS  CHROMOSOME  GENE  SNPs  HAPLOTYPE  FREQUENCY  
WIN7  8  TOP1mt  rs2293925|rs724037|rs11544484  GTC  0.225  
WIN7  8  TOP1mt  rs2293925|rs724037|rs11544484  GTT  0.570  
WIN8  8  TOP1mt  rs724037|rs11544484|rs2450772  GCA  0.139  
WIN8  8  TOP1mt  rs724037|rs11544484|rs2450772  TCA  0.015  
WIN8  8  TOP1mt  rs724037|rs11544484|rs2450772  TTA  0.228  
WIN8  8  TOP1mt  rs724037|rs11544484|rs2450772  GCG  0.065  
WIN8  8  TOP1mt  rs724037|rs11544484|rs2450772  TCG  0.208  
WIN8  8  TOP1mt  rs724037|rs11544484|rs2450772  TTG  0.342  
WIN9  10  TFAM  rs11006126|rs2306604|rs1049432  CGT  0.213  
WIN9  10  TFAM  rs11006126|rs2306604|rs1049432  TGT  0.011  
WIN9  10  TFAM  rs11006126|rs2306604|rs1049432  CAG  0.053  
WIN9  10  TFAM  rs11006126|rs2306604|rs1049432  TAG  0.150  
WIN9  10  TFAM  rs11006126|rs2306604|rs1049432  CGG  0.047  
WIN9  10  TFAM  rs11006126|rs2306604|rs1049432  TGG  0.527  
WIN10  10  TFAM  rs2306604|rs1049432|rs11006132  GTG  0.224  
WIN10  10  TFAM  rs2306604|rs1049432|rs11006132  AGA  0.203  
WIN10  10  TFAM  rs2306604|rs1049432|rs11006132  GGA  0.565  
WIN11  10  TFAM-C10orf2  rs1049432|rs11006132|rs17113613  TGA  0.036  
WIN11  10  TFAM-C10orf2  rs1049432|rs11006132|rs17113613  GAA  0.104  
WIN11  10  TFAM-C10orf2  rs1049432|rs11006132|rs17113613  TGG  0.188  
WIN11  10  TFAM-C10orf2  rs1049432|rs11006132|rs17113613  GAG  0.665  
WIN12  10  TFAM-C10orf2  rs11006132|rs17113613|rs3740485  GAC  0.035  
WIN12  10  TFAM-C10orf2  rs11006132|rs17113613|rs3740485  AAC  0.105  
WIN12  10  TFAM-C10orf2  rs11006132|rs17113613|rs3740485  GGC  0.062  
WIN12  10  TFAM-C10orf2  rs11006132|rs17113613|rs3740485  AGC  0.191  
WIN12  10  TFAM-C10orf2  rs11006132|rs17113613|rs3740485  GGT  0.133  
WIN12  10  TFAM-C10orf2  rs11006132|rs17113613|rs3740485  AGT  0.474  
WIN13  10  C10orf2  rs17113613|rs3740485|rs3740486  ACT  0.141  
WIN13  10  C10orf2  rs17113613|rs3740485|rs3740486  GCT  0.245  
WIN13  10  C10orf2  rs17113613|rs3740485|rs3740486  GTC  0.609  
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LOCUS  CHROMOSOME  GENE  SNPs  HAPLOTYPE  FREQUENCY  
WIN14  10  C10orf2  rs3740485|rs3740486|rs11190787  CTG  0.379  
WIN14  10  C10orf2  rs3740485|rs3740486|rs11190787  TCT  0.609  
WIN17  17  POLG2  rs9905016|rs2075551  TC  0.169  
WIN17  17  POLG2  rs9905016|rs2075551  CC  0.033  
WIN17  17  POLG2  rs9905016|rs2075551  CG  0.799  
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3.7.2 LD analysis  
With the aid of HaploView v4.2 software, linkage disequilibrium was assessed 
within the six genes with > 1 SNP, TOP1mt (5 SNPs), C10orf2 (4 SNPs), TFAM (4 
SNPs), PINK (3 SNPs), NRF2 (3 SNPs) and POLG2 (2 SNPs).  Haplotype blocks 
per gene were generated (Figure 3.8) and due to few markers being interrogated 
per gene, the haplotype blocks covered small regions of the entire gene of interest. 
Many but not all of the SNPs within each gene were in strong LD. All studied 
SNPs in C10orf2, PINK1 and POLG2 were in strong LD whereas different linkage 
blocks were observed for the SNPs studied in TOP1mt, TFAM and NRF2.   
  
Figure 3.8: LD plot of the interrogated SNP markers (Pairwise LD).  
The SNP ID is displayed along the top of the diagram. Colours represent D′ values (dark red=high 
inter-SNP D′; blue=statistically ambiguous D′; white=low inter-SNP D′), and r2 values are 
contained within blocks (bold=high r2).  
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3.8 Associations between alleles, genotypes, haplotypes and SN.  
3.8.1 Univariate analysis of associations between genetic variation and SN  
When we compared allele frequencies in cases with SN ever vs controls without 
SN ever we found that SNP rs1962142 in the NRF2 gene was protective against 
HIVSN (chi squared P = 0.038 and pEMP1 = 0.029) (Table 3.10), while SNP 
rs724037 (TOP1mt) was significantly associated with the development of SN (chi -
squared P = 0.047). SNP rs2856268 (POLG) was border line significantly 
associated with the development of SN (chi squared P = 0.07 and pEMP1 = 0.07). 
However, the associations of all three SNPs (rs1962142, rs724037 and rs2856268) 
were found to be insignificant after Bonferroni or pEMP2 correction for multiple 
testing.   
When we compared genotype frequencies in cases with SN vs controls without SN 
(Table 3.11), we found that NRF2 rs1962142 genotypes were significant for 
protective effect against SN development (Fishers P = 0.037, pEMP1=0.028) for 
both genotypic and dominant models. POLG rs2856268 genotypes were also 
significantly associated with SN (Fishers P = 0.04, pEMP1=0.04) for the dominant 
model.  Both of these SNPs were therefore associated with SN in both allelic and 
genotypic models.  Genotypes of the TOP1mt SNP rs724037 (that had significant 
allelic association with SN), were not significantly associated with SN for all three 
genotypic models (P > 0.05).  All P-values became non-significant when 
Bonferroni or pEMP2 corrections were applied. 
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Table 3.10. Basic association test of alleles with the phenotype SN.  
Gene  SNP ID  MAF in 
Cases  
MAF  
Controls  
OR  Chi-SQ   
P-value  
  
Bonferroni  
P-value  
  
EMP1  EMP2  
PINK  
rs10799655  
0.29  0.30  0.94  
0.750  1  0.760  1  
rs650616  
0.43  0.41  1.05  
0.797  1  0.833  1  
rs622525  
0.16  0.20  0.79  
0.315  1  0.338  0.999  
CCDC19  
rs2501325  
0.13  0.14  0.89  
0.646  1  0.703  1  
ZFN648  
rs7554182  
0.28  0.23  1.29  
0.221  1  0.239  0.995  
  
NRF2  rs1962142  
0.04  0.09  0.47  
0.039*  1  0.029*  0.571  
rs35652124  
0.17  0.19  0.90  
0.637  1  0.633  1  
rs2886162  
0.44  0.43  1.06  
0.739  1  0.719  1  
NFE2L3  
rs4722585  
0.28  0.23  1.26  
0.268  1  0.323  0.998  
  
  
TOP1mt  
rs7387720  
0.22  0.20  1.18  
0.450  1  0.524  1  
rs2293925  
0.02  0.01  1.64  
0.565  1  0.691  1  
rs724037  0.24  0.16  1.59  0.047*  1  0.061  0.631  
rs11544484  
0.45  0.40  1.21  
0.300  1  0.323  0.999  
rs2450772  
0.39  0.38  1.08  
0.675  1  0.706  1  
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Gene  SNP ID  MAF in 
Cases  
MAF  
Controls  
OR  Chi-SQ   
P-value  
  
Bonferroni  
P-value  
  
EMP1  EMP2  
   
 
TFAM  
rs11006126  
0.31  0.32  0.93  
0.697  1  0.774  1  
rs2306604  
0.19  0.22  0.79  
0.295  1  0.314  0.999  
rs1049432  
0.21  0.24  0.87  
0.534  1  0.591  1  
rs11006132  
0.22  0.24  0.88  
0.552  1  0.563  1  
  
C10orf2  
rs17113613  
0.15  0.13  1.16  
0.578  1  0.597  1  
rs3740485  
0.39  0.39  0.98  
0.916  1  0.925  1  
rs3740486  
0.39  0.38  1.01  
0.962  1  1  1  
C10orf2  
rs11190787  
0.38  0.38  0.99  
0.965  1  0.981  1  
POLG  
rs2856268  
0.16  0.11  1.62  
0.073  1  0.074  0.793  
LITAF  
rs13333308  
0.10  0.10  1.01  
0.969  1  1  1  
POLG2  
rs9905016  
0.17  0.16  1.09  
0.726  1  0.776  1  
rs2075551  
0.20  0.21  0.98  
0.931  1  1  1  
Significant P-value indicated by  *      
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Table 3.11. Association of genotypes with SN using three genotype models.  
GENE  SNP ID  Genotype 
Model  
Genotype  
Counts in Cases  
Genotype 
counts in  
Controls  
Chi-Squared or 
Fisher’s Exact  
Test   P-value  
(Uncorrected)  
  
P-value  
Bonferroni  
(Corrected)  
EMP1  EMP2   
PINK1  
rs10799655  
Genotypic  10/59/67  8/52/52  0.904  1  0.904  1  
Dominant  69/67  60/52  0.702  1  0.699  1  
Recessive  10/126  8/104  1  1  1  1  
PINK1  
rs650616  
Genotypic  22/71/42  20/52/39  0.679  1  0.676  1  
Dominant  93/42  72/39  0.586  1  0.538  1  
Recessive  22/113  20/91  0.736  1  0.700  1  
PINK1  
rs622525  
Genotypic  5/34/97  2/40/70  0.151  1  0.152  0.964  
Dominant  39/97  42/70  0.174  1  0.173  0.963  
Recessive  5/131  2/110  0.462  1  0.462  0.999  
CCDC19  
rs2501325  
Genotypic  4/27/105  3/26/83  0.833  1  0.832  1  
Dominant  31/105  29/83  0.655  1  0.655  1  
Recessive  4/132  3/109  1  1  1  1  
ZNF648  
rs7554182  
Genotypic  9/57/70  4/43/65  0.426  1  0.429  1  
  Dominant  66/70  47/65  0.309  1  0.308  0.999  
Recessive  9/127  4/108  0.393  1  0.394  0.999  
NRF2  
rs1962142  
Genotypic  0/12/124  0/20/91  0.037*  1  0.028*  0.548  
Dominant  12/124  20/91  0.037*  1  0.029*  0.496  
Recessive  0/136  0/111  1  1  1  1  
NRF2  
rs35652124  
Genotypic  5/37/94  2/38/71  0.430  1  0.425  1  
Dominant  42/94  40/71  0.417  1  0.376  1  
Recessive  5/131  2/109  0.464  1  0.463  0.999  
NRF2  rs2886162  Genotypic  30/60/45  15/61/30  0.102  1  0.102  0.892  
  Dominant 90/45 76/30 0.484 1 0.402 1 
Recessive 30/105 15/91 0.134 1 0.102 0.884 
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GENE  SNP ID  Genotype 
Model  
Genotype  
Counts in 
Cases  
Genotype 
counts in  
Controls  
Chi-Squared or 
Fisher’s Exact  
Test   P-value  
(Uncorrected)  
  
P-value  
Bonferroni  
(Corrected)  
EMP1  EMP2   
NRF3/NFE 
2L3 
rs4722585 
Genotypic 13/49/74 7/38/67 0.546 1 0.547 1 
Dominant 62/74 45/67 0.440 1 0.440 1 
Recessive 13/123 7/105 0.362 1 0.362 0.999 
TOP1MT 
rs7387720 
Genotypic 9/43/84 5/34/73 0.767 1 0.768 1 
Dominant 52/84 39/73 0.5988 1 0.5976 1 
Recessive 9/127 5/107 0.585 1 0.584 1 
TOP1MT 
rs2293925 
Genotypic 0/4/132 0/2/109 0.693 1 0.691 1 
Dominant 4/132 2/109 0.693 1 0.692 1 
Recessive 0/136 0/111 1 1 1 1 
TOP1MT 
rs724037 
Genotypic 10/43/81 4/27/77 0.170 1 0.169 0.977 
Dominant 53/81 31/77 0.103 1 0.083** 0.858 
Recessive 10/124 4/104 0.273 1 0.263 0.991 
TOP1MT 
rs11544484 
Genotypic 28/65/42 19/52/41 0.596 1 0.595 1 
Dominant 93/42 71/41 0.417 1 0.383 1 
Recessive 28/107 19/93 0.516  0.470 1 
TOP1MT 
rs2450772 
Genotypic 19/69/48 15/54/43 0.893 1 0.892 1 
Dominant 88/48 69/43 0.692 1 0.691 1 
Recessive 19/117 15/97 1 1 1 1 
TFAM 
rs11006126 
Genotypic 16/51/69 10/52/50 0.357 1 0.355 0.999 
Dominant 67/69 62/50 0.373 1 0.370 0.999 
Recessive 16/120 10/102 0.536 1 0.534 1 
TFAM 
rs2306604 
Genotypic 5/40/90 5/40/67 0.528 1 0.526 1 
Dominant 45/90 45/67 0.290 1 0.292 0.998 
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GENE  SNP ID  Genotype 
Model  
Genotype  
Counts in 
Cases  
Genotype 
counts in  
Controls  
Chi-Squared or 
Fisher’s Exact  
Test   P-value  
(Uncorrected)  
  
P-value  
Bonferroni  
(Corrected)  
EMP1  EMP2   
TFAM  Recessive 5/130 5/107 0.759 1 0.758 1 
TFAM rs1049432 Genotypic 8/42/86 5/43/64 0.459 1 0.462 1 
  Dominant  50/86  48/64  0.362  1  0.361  0.999  
Recessive  8/128  5/107  0.777  1  0.780  1  
TFAM  
rs11006132  
Genotypic  9/42/85  6/42/63  0.524  1  0.522  1  
Dominant  51/85  48/63  0.365  1  0.362  0.999  
Recessive  9/127  6/105  0.793  1  0.794  1  
C10orf2  
rs17113613  
Genotypic  3/34/98  1/27/83  0.799  1  0.781  1  
Dominant  37/98  28/83  0.772  1  0.751  1  
Recessive  3/132  1/110  0.629  1  0.567  1  
C10orf2  
rs3740485  
Genotypic  19/65/49  18/51/42  0.867  1  0.857  1  
Dominant  84/49  69/42  0.895  1  0.896  1  
Recessive  19/114  18/93  0.722  1  0.708  1  
C10orf2  
rs3740486  
Genotypic  18/69/49  18/50/44  0.611  1  0.611  1  
Dominant  87/49  68/44  0.601  1  0.603  1  
Recessive  18/118  18/94  0.589  1  0.587  1  
C10orf2  
rs11190787  
Genotypic  19/62/51  17/49/43  0.953  1  0.943  1  
Dominant  81/51  66/43  1  1  0.996  1  
Recessive  19/113  17/92  0.857  1  0.813  1  
POLG  
  
rs2856268  
  
Genotypic  2/40/93  2/20/90  
  
0.087**  
  
1  
  
0.086**  
  
0.839  
Dominant  42/93  22/90  0.043*  1  0.042*  0.569  
Recessive  2/133  2/110  1  1  0.834  1  
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GENE  SNP ID  Genotype 
Model  
Genotype  
Counts in 
Cases  
Genotype 
counts in  
Controls  
Chi-Squared or 
Fisher’s Exact  
Test   P-value  
(Uncorrected)  
  
P-value  
Bonferroni  
(Corrected)  
EMP1  EMP2   
LITAF  
rs13333308  
Genotypic  1/25/110  0/22/90  0.930  1  0.930  1  
Dominant  26/110  22/90  1  1  1  1  
Recessive  1/135  0/112  1  1  1  1  
POLG2 
rs9905016 
Genotypic 6/35/94 5/26/80 0.943 1 0.930 1 
Dominant 41/94 31/80 0.778 1 0.725 1 
Recessive 6/129 5/106 1 1 0.927 1 
POLG2 
rs2075551 
Genotypic 7/41/88 6/34/72 1 1 1 1 
Dominant 48/88 40/72 1 1 1 1 
Recessive 7/129 6/106 1 1 1 1 
Significant P-value indicated by  *      
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The haplotype frequencies in the SN positive and SN negative group were compared. 
Asymptotic P-values were also generated (Table 3.12), for all haplotypes. Two 
haplotypes were significantly associated with SN (Table 3.12). The haplotype 
rs7387720|rs2293925|rs724037 GGT in TOP1mt conferred a protective effect against 
the development of SN (P = 0.004). This haplotype included rs724037 that was 
associated with SN in an allelic model.   Another haplotype in TOP1mt also containing 
this SNP, rs2293925|rs724037|rs11544484 GGC, was weakly associated with SN (P = 
0.08 on Table 3.12). The TFAM rs11006126|rs2306604|rs1049432 CGG haplotype was 
significantly associated with the development of SN (P = 0.021).  None of the SNPs in 
this haplotype were independently associated with SN risk in allelic or genotypic mode
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Table 3.12 Haplotype association (Univariate) with SN.  
LOCUS  HAPLOTYPE  CASES  CONTROLS  P-value  pEMP1 pEMP2 SNPS  GENES  
WIN1  TGA  0.158  0.192  0.322  0.333 1 rs10799655|rs650616|rs622525  PINK  
WIN1  CAT  0.429  0.418  0.811  0.817 1 rs10799655|rs650616|rs622525  PINK  
WIN1  TGT  0.133  0.113  0.494  0.489 1 rs10799655|rs650616|rs622525  PINK  
WIN1  CGT  0.279  0.277  0.945  0.944 1 rs10799655|rs650616|rs622525  PINK  
WIN2  GAC  0.009  0.012  0.764  0.661 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN2  ATC  0.047  0.058  0.567  0.497 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN2  GTC  0.073  0.073  0.999  0.998 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN2  GAA  0.153  0.185  0.343  0.340 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN2  ATA  0.380  0.357  0.602  0.582 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN2  GTA  0.339  0.315  0.581  0.582 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN3  TCT  0.032  0.017  0.308  0.168 0.999 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
WIN3  AAT  0.037  0.043  0.752  0.687 1 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
WIN3  TAT  0.201  0.159  0.232  0.191 0.999 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
WIN3  TCC  0.090  0.116  0.337  0.319 1 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
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Locus  Haplotype  Cases  Controls  P-value  pEMP1 pEMP2 SNPS  GENES  
WIN3  AAC  0.118  0.145  0.374  0.381 1 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
WIN3  TAC  0.523  0.520  0.951  0.922 1 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
WIN4  ATA  0.040  0.071  0.133  0.126 0.991 rs1962142|rs35652124|rs2886162  NRF2  
WIN4  GTA  0.405  0.368  0.415  0.329 1 rs1962142|rs35652124|rs2886162  NRF2  
WIN4  GCG  0.174  0.189  0.669  0.711 1 rs1962142|rs35652124|rs2886162  NRF2  
WIN4  GTG  0.382  0.372  0.824  0.682 1 rs1962142|rs35652124|rs2886162  NRF2  
WIN6  GAG  0.013  0.009  0.658  0.510 1 rs7387720|rs2293925|rs724037  TOP1mt  
WIN6  GGG  0.207  0.150  0.101  0.102 0.988 rs7387720|rs2293925|rs724037  TOP1mt  
WIN6  AGG  0.019  0.014  0.674  0.689 1 rs7387720|rs2293925|rs724037  TOP1mt  
WIN6  GGT  0.003  0.037  0.004*  0.012* 0.689 rs7387720|rs2293925|rs724037  TOP1mt  
WIN6  AGT  0.758  0.790  0.406  0.421 1 rs7387720|rs2293925|rs724037  TOP1mt  
WIN7  AGC  0.015  0.009  0.562  0.425 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN7  GGC  0.220  0.158  0.080  0.086 0.958 rs2293925|rs724037|rs11544484  TOP1mt  
WIN7  GTC  0.215  0.237  0.557  0.577 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN7  GTT  0.550  0.596  0.304  0.337 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN8  GCA  0.155  0.122  0.297  0.295 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TCA  0.021  0.009  0.272  0.149 0.999 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TTA  0.218  0.242  0.531  0.518 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  GCG  0.081  0.047  0.129  0.087 0.980 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TCG  0.192  0.226  0.356  0.382 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TTG  0.333  0.355  0.619  0.626 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN9  CGT  0.198  0.232  0.362  0.331 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  TGT  0.015  0.005  0.265  0.229 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  CAG  0.041  0.067  0.190  0.160 0.998 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  TAG  0.145  0.156  0.726  0.711 1 rs11006126|rs2306604|rs1049432  TFAM  
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LOCUS  HAPLOTYPE  CASES  CONTROLS  P- value pEMP1 pEMP2 SNPS  GENES  
WIN9  CGG  0.066  0.022  0.021*  0.020* 0.633 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  TGG  0.535  0.518  0.701  0.681 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN10  GTG  0.215  0.239  0.527  0.556 1 rs2306604|rs1049432|rs11006132  TFAM  
WIN10  AGA  0.187  0.225  0.297  0.293 1 rs2306604|rs1049432|rs11006132  TFAM  
WIN10  GGA  0.598  0.536  0.167  0.173 0.998 rs2306604|rs1049432|rs11006132  TFAM  
WIN11  TGA  0.034  0.039  0.737  0.616 1 rs1049432|rs11006132|rs17113613  TFAM-C10orf2  
WIN11  GAA  0.114  0.093  0.442  0.400 1 rs1049432|rs11006132|rs17113613  TFAM-C10orf2  
WIN11  TGG  0.181  0.200  0.607  0.584 1 rs1049432|rs11006132|rs17113613  TFAM-C10orf2  
WIN11  GAG  0.671  0.669  0.951  0.924 1 rs1049432|rs11006132|rs17113613  TFAM-C10orf2  
WIN12  GAC  0.035  0.036  0.916  0.890 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  AAC  0.114  0.095  0.491  0.466 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  GGC  0.057  0.069  0.578  0.585 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  AGC  0.188  0.194  0.857  0.834 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  GGT  0.129  0.138  0.777  0.777 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  AGT  0.478  0.468  0.826  0.798 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN13  ACT  0.149  0.132  0.597  0.566 1 rs17113613|rs3740485|rs3740486  C10orf2  
WIN13  GCT  0.239  0.255  0.670  0.714 1 rs17113613|rs3740485|rs3740486  C10orf2  
WIN13  GTC  0.613  0.613  0.999  0.943 1 rs17113613|rs3740485|rs3740486  C10orf2  
WIN14  CTG  0.383  0.385  0.969  0.949 1 rs3740485|rs3740486|rs11190787  C10orf2  
WIN14  TCT  0.617  0.616  0.969  0.943 1 rs3740485|rs3740486|rs11190787  C10orf2  
WIN17  TC  0.174  0.162  0.726  0.770 1 rs9905016|rs2075551  POLG2  
WIN17  CC  0.026  0.041  0.363  0.337 1 rs9905016|rs2075551  POLG2  
WIN17  CG  0.800  0.797  0.941  0.935 1 rs9905016|rs2075551  POLG2  
P-value (Significant)  shown by *   
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3.8.2 Multivariate analysis of association with SN 
Multivariate analysis was performed only on SNPs, genotypes and haplotypes 
with P-values <0.5 during univariate analysis of association with SN. The 
multivariate analysis involved inclusion of covariates that were significant during 
analyses of demographic data i.e. age and height. These covariates were tested as 
to whether they had any additive effect on the development of SN. Logistic 
regressions (OR) results are shown for categorical data (SN).   
  
All the alleles and genotypes that were found to be significantly associated with 
SN in univariate analysis were found to be non-significant when tested using 
multivariate analysis (Table 3.13 and Table 3.14).  
  
Table 3.13. Logistic regression analysis of association between alleles and SN 
including age and height as covariates.   
Gene  SNP  P-Value   Bonferroni 
P-value  
EMP1  EMP2  OR  
NRF2  rs1962142  0.137  1  0.134  0.947  0.543  
TOP1mt  rs724037  0.083  1  0.080  0.835  1.510  
POLG  rs2856268  0.244  1  0.226  0.999  1.413  
  
Genotypic analysis including the covariates yielded no significant P-values for all 
SNPs (rs1962142, rs724037, rs2856268 & P = NA, 0.22, 0.32) respectively 
(Table 3.14). The rs1962142 SNP generated a not available (NA) result when 
interrogated for any additive effect to the phenotype of SN.  
Table 3.14: Logistic regression analysis of association between genotypes and 
SN including age and height as covariates  
Gene  SNP  Genotypic 
model   
P- 
Value  
Bonferroni 
P-value  
EMP1  EMP2  OR  
NRF2  rs1962142  Genotypic  NA  1  1  1  NA  
NRF2  rs1962142  Dominant  0.137  1  0.125  0.948  0.543  
POLG  rs2856268  Genotypic  0.323  1  0.578  1  2.263  
POLG  rs2856268  Dominant  0.440  1  0.184  0.989  0.792  
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The three haplotypes that were significantly associated with SN in univariate analysis in 
Table 3.12 were tested for association using the multivariate model (using age and height as 
cofactors) and two maintained their significance (Table 3.15). Empirical P-value (pEMP1) 
was also computed for the significant haplotypes using hundred thousand (100 000) 
permutations. The haplotypes maintained their significance (Table 3.15). The haplotype 
GGT had a significant pEMP1 of 0.007 and haplotype CGG had a significant pEMP1 of 
0.017. The TOP1mt haplotype GGC which was borderline significant during univariate 
analysis was found to be non-significant during multivariate analysis. All haplotypes were 
non-significant after correction for pEMP2.  
  
Table 3.15. Additive effect of age and height to haplotype association with SN (Logistic 
regression analysis).  
GENE  HAPLOTYPE  FREQUENCY  OR  STAT  P-
VALUE  
EMP1  EMP2  
TOP1mt  rs7387720|rs2293925|rs724037 
(GGT)  
0.019*  0.04  4.44  0.035*  0.007*  0.703  
TOP1mt  rs2293925|rs724037|rs11544484 
(GGC)  
0.191  1.47  2.5  0.114  0.114  0.987  
TFAM  rs11006126|rs2306604|rs1049432 
(CGG)  
0.047 * 3.82  4.87  0.027 * 0.017*  0.609  
  Significant P-value indicated by  *       
A summary of all the alleles, genotypes and haplotypes that were significantly (P<0.05) 
associated in univariate analysis with SN, and results after multivariate analysis is shown in 
Table 3.15 below. 
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Table 3.16: Summary of results from association of genetic variants with SN.  
     Univariate analyses   Multivariate analyses   
Gene  SNP  Model  Associated with  P  pEMP1  OR  P-value  pEMP1  pEMP2  OR  
NRF2  rs1962142  Allelic  SN  0.039*  0.029 * 0.47  0.137  0.134  0.947  0.54  
NRF2  rs1962142  Dominant   SN  0.037*  0.028*  -  0.137  0.125  0.948  0.54  
NRF2  rs1962142  Genotypic   SN  0.037*  0.029*  -  NA  1  1  NA  
POLG  rs2856268  Dominant  SN  0.043*  0.041*  -  0.440  0.184  0.989  0.792  
TOP1mt  rs724037  Allelic  SN  0.047*  0.061  1.62  0.083  0.080  0.835  1.51  
TOP1mt  rs7387720|rs2293925|rs724 
037  
Haplotype 
(GGT)  
SN  0.004*  0.012*  0.04  0.035 * 0.007*  0.703  0.04  
TFAM  rs11006126|rs2306604  
|rs1049432  
  
Haplotype 
(CGG)   
SN  0.021*  0.020*  3.82  0.027 * 0.017*  0.609  3.82  
Significant P-value indicated by *       
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3.9 Associations between alleles, genotype, haplotypes and pain intensity  
3.9.1 Univariate Associations between genetic variants and pain intensity 
When we compared pain intensity phenotype to SNP risk allele, we found that 
NRF3 gene SNP (rs4722585) was significantly associated with increased pain 
intensity (T-test P = 0.014 and pEMP1 = 0.014) (Table 3.16). The rs7387720 SNP 
of TOP1mt gene was border-line significant for association with decreased pain 
intensity (T-test P = 0.052 and pEMP1 = 0.053) (Table 3.16). However, these 
associations were not significant after adjustments for multiple testing.   
When we performed genotype association with pain intensity (Table 3.17) we 
found that the NRF SNP rs4722585 was significantly associated with an increase 
in pain intensity (T-test P = 0.045; pEMP1 = 0.059) and (T-test P = 0.018; pEMP1 
= 0.023) for both the genotypic and dominant models, respectively. The 
rs7387720 SNP in TOP1mt was also significant for protective effect against pain 
intensity (T-test P = 0.030; pEMP1 = 0.033) for the dominant model. All P-values 
became non-significant when Bonferroni or pEMP2 corrections were applied. 
SNPs in blue in the Table below had the lowest P-values for association with pain 
intensity in the cohort but all were above significance level of 0.05.  
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Table 3.17. Basic association test of alleles with the phenotype pain intensity.  
Gene  SNP ID  Beta  T-test  
P-value  
  
Bonferroni   
P-value  
  
pEMP1  pEMP2  
PINK  rs10799655  0.141  0.101  1  0.099  0.886  
rs650616  -0.119  0.171  1  0.171  0.977  
rs622525  0.115  0.182  1  0.184  0.982  
CCDC19  rs2501325  0.056  0.517  1  0.532  1  
ZNF648  rs7554182  -0.032  0.710  1  0.717  1  
  
NRF2  
rs1962142  -0.066  0.449  1  0.465  1  
rs35652124  0.091  0.295  1  0.300  0.999  
rs2886162  0.036  0.678  1  0.676  1.000  
NRF3  rs4722585  0.209  0.014*  0.377  0.014*  0.260  
  
  
TOP1mt  
rs7387720  -0.166  0.053**  1  0.053  0.673  
rs2293925  -0.084  0.330  1  0.352  1.000  
rs724037  -0.146  0.093  1  0.093  0.863  
rs11544484  -0.105  0.226  1  0.225  0.994  
rs2450772  0.073  0.397  1  0.405  1  
  
  
TFAM  
rs11006126  0.076  0.382  1  0.390  1  
rs2306604  0.018  0.839  1  0.838  1  
rs1049432  0.051  0.558  1  0.563  1  
rs11006132  0.019  0.831  1  0.835  1  
  
C10orf2  
rs17113613  -0.103  0.233  1  0.234  0.995  
rs3740485  -0.061  0.486  1  0.483  1  
rs3740486  -0.076  0.381  1  0.378  1  
C10orf2  rs11190787  -0.050  0.568  1  0.567  1  
POLG  rs2856268  -0.020  0.820  1  0.820  1  
LITAF  rs13333308  0.015  0.861  1  0.868  1  
POLG2  rs9905016  0.085  0.326  1  0.329  1  
rs2075551  0.118  0.171  1  0.172  0.977  
P-value (Significant)    : *  
P-value (border line Significant)  : **  
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Table 3.18. Association of genotypes with pain intensity using three models of genotype inheritance.   
GENE  SNP ID  Genotype Model  Beta  STAT  T-test   P- 
Value   
  
P-value 
Bonferroni  
EMP1  EMP2   
PINK1  
rs10799655  
Genotypic  NA  5.67  0.715  1  0.727  1  
Dominant  0.188  2.209  0.029  0.750  0.031  0.499  
Recessive  -0.021  -0.242  0.809  1  0.810  1  
PINK1  
rs650616  
Genotypic  NA  3.37  0.185  1  0.112  0.893  
Dominant  -0.046  -0.534  0.594  1  0.598  1  
Recessive  -0.158  -1.843  0.068**  1  0.057  0.715  
PINK1  
rs622525  
Genotypic  NA  2.07  0.355  1  0.605  1  
Dominant  0.124  1.443  0.151  1  0.148  0.973  
Recessive  0.033  0.388  0.699  1  0.719  1  
CCDC19  
rs2501325  
Genotypic  NA  0.70  0.706  1  0.398  1  
Dominant  0.039  0.447  0.656  1  0.659  1  
Recessive  0.070  0.814  0.417  1  0.450  1  
ZFN648  
rs7554182  
Genotypic  NA  0.22  0.894  1  0.659  1  
  Dominant  -0.020  -0.230  0.818  1  0.802  1  
Recessive  -0.040  -0.463  0.645  1  0.638  1  
NRF2  
rs1962142  
Genotypic  NA  NA  NA  1  1  1  
Dominant  -0.066  -0.76  0.449  1  0.429  1  
Recessive  NA  NA  NA  1  1  1  
NRF2  
rs35652124  
Genotypic  NA  2.31  0.316  1  0.149  0.950  
Dominant  0.055  0.633  0.528  1  0.547  1  
Recessive  0.129  1.510  0.133  1  0.109  0.934  
NRF2  
rs2886162  
Genotypic  NA  0.59  0.745  1  0.609  1  
Dominant  0.001  0.017  0.987  1  0.985  1  
      P-value (Significant)    : *  
      P-value (border line Significant)  : **  
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GENE  SNP ID  Genotype Model  Beta  STAT  T-test   P- 
Value   
  
P-value 
Bonferroni  
EMP1  EMP2   
  Recessive  0.062  0.719  0.473  1  0.472  1  
NRF3  
rs4722585  
Genotypic  NA  6.20  0.045  1  0.059  0.618  
Dominant  0.202  2.386  0.018  0.479  0.023  0.365  
Recessive  0.129  1.510  0.133  1  0.150  0.936  
TOP1MT  
rs7387720  
Genotypic  NA  4.82  0.090**  1  0.357  1  
Dominant  -0.186  -2.195  0.030  0.776  0.033  0.511  
Recessive  -0.048  -0.556  0.579  1  0.577  1  
TOP1MT  
rs2293925  
Genotypic  NA  NA  NA  1  1  1  
Dominant  -0.084  -0.978  0.330  1  0.326  1  
Recessive  NA  NA  NA  1  1  1  
TOP1MT  
rs724037  
Genotypic  NA  3.16  0.206  1  0.303  1  
Dominant  -0.153  -1.777  0.078**  1  0.076  0.835  
Recessive  -0.066  -0.757  0.451  1  0.458  1  
TOP1MT  
rs11544484  
Genotypic  NA  2.57  0.277  1  0.178  0.981  
Dominant  -0.041  -0.469  0.640  1  0.613  1  
Recessive  -0.138  -1.606  0.111  1  0.097  0.884  
TOP1MT  
rs2450772  
Genotypic  NA  3.60  0.165  1  0.165  0.980  
Dominant  -0.008  -0.094  0.925  1  0.931  1  
  Recessive  0.152  1.784  0.077**  1  0.070  0.774  
TFAM  
rs11006126  
Genotypic  NA  0.83  0.662  1  0.503  1  
Dominant  0.077  0.898  0.371  1  0.412  1  
Recessive  0.041  0.479  0.632  1  0.636  1  
TFAM  
rs2306604  
Genotypic  NA  0.21  0.899  1  0.866  1  
Dominant  0.028  0.329  0.743  1  0.727  1  
P-value (Significant)    : *  
P-value (border line Significant)  : **  
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GENE  SNP ID  Genotype Model  Beta  STAT  T-test   P- 
Value   
  
P-value 
Bonferroni  
EMP1  EMP2   
TFAM 
 
rs2306604 Recessive  -0.019  -0.223  0.824  1  0.839  1  
TFAM rs1049432 Genotypic  NA  0.94  0.624  1  0.359  1  
Dominant  0.022  0.260  0.795  1  0.803  1  
Recessive  0.084  0.973  0.332  1  0.358  1  
TFAM  
rs11006132  
Genotypic  NA  0.24  0.887  1  0.685  1  
Dominant  0.003  0.030  0.976  1  0.978  1  
Recessive  0.041  0.472  0.638  1  0.630  1  
C10orf2  
rs17113613  
Genotypic  NA  3.90  0.142  1  0.144  0.603  
Dominant  -0.061  -0.704  0.483  1  0.501  1  
Recessive  -0.168  -1.967  0.051**  1  0.057  0.603  
C10orf2  
rs3740485  
Genotypic  NA  0.82  0.663  1  0.402  1  
Dominant  -0.028  -0.325  0.746  1  0.771  1  
Recessive  -0.079  -0.909  0.365  1  0.354  1  
C10orf2  
rs3740486  
Genotypic  NA  0.98  0.612  1  0.347  1  
Dominant  -0.047  -0.541  0.5896  1  0.611  1  
Recessive  -0.082  -0.955  0.341  1  0.331  1  
C10orf2  
rs11190787  
Genotypic  NA  0.52  0.770  1  0.504  1  
Dominant  -0.025  -0.285  0.7762  1  0.786  1  
Recessive  -0.063  -0.725  0.470  1  0.467  1  
POLG  
  
rs2856268  
  
Genotypic  NA  1.14  0.565  1  0.452  1  
Dominant  -0.041  -0.470  0.639  1  0.646  1  
Recessive  0.074  0.859  0.392  1  0.433  1  
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GENE  SNP ID  Genotype Model  Beta  STAT  T-test   P- 
Value   
  
P-value 
Bonferroni  
EMP1  EMP2   
LITAF  
rs13333308  
Genotypic  NA  0.03  0.985  1  0.966  1  
Dominant  0.015  0.173  0.8631  1  0.891  1  
Recessive  0.005  0.062  0.951  1  0.988  1  
POLG2  
rs9905016  
Genotypic  NA  1.70  0.427  1  0.196  0.985  
Dominant  0.054  0.628  0.531  1  0.475  1  
Recessive  0.111  1.290  0.199  1  0.203  0.989  
POLG2  
rs2075551  
Genotypic  NA  3.21  0.201  1  0.074  0.768  
Dominant  0.075  0.874  0.384  1  0.351  1  
  Recessive  0.151  1.764  0.080**  1  0.080  0.786  
      P-value (Significant)    : *  
      P-value (border line Significant)  : **  
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When we compared pain intensity to haplotypes, we found that there was no significant 
association with all haplotypes (Table 3.19). All computed P-values were (P > 0.05). The 
haplotypes in blue in the table below had the lowest P-values (< 0.1 but > 0.05). 
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Table 3.19. Haplotype Association with pain intensity.  
LOCUS  HAPLOTYPE  Beta  R2  STAT  P-value pEMP1 pEMP2 SNPS  GENES  
WIN1  TGA  0.858  0.016  1.466  0.145  0.157 1 rs10799655|rs650616|rs622525  PINK  
WIN1  CAT  -0.646  0.014  -1.377  0.171  0.165 1 rs10799655|rs650616|rs622525  PINK  
WIN1  TGT  0.341  0.002  0.509  0.612  0.604 1 rs10799655|rs650616|rs622525  PINK  
WIN1  CGT  -0.034  0.000  -0.068  0.946  0.954 1 rs10799655|rs650616|rs622525  PINK  
WIN2  ATC  -0.831  0.004  -0.695  0.489  0.502 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN2  GTC  1.241  0.014  1.395  0.165  0.177 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN2  GAA  0.803  0.013  1.343  0.182  0.193 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN2  ATA  -0.576  0.010  -1.162  0.247  0.244 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN2  GTA  -0.226  0.002  -0.456  0.649  0.637 1 rs650616|rs622525|rs2501325  PINK – CCDC19  
WIN3  TCT  1.762  0.011  1.205  0.230  0.239 1 rs622525|rs2501325|rs7554182  PINK – CCDC19  
WIN3  AAT  -0.896  0.002  -0.543  0.588  0.598 1 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
WIN3  TAT  -0.433  0.004  -0.714  0.476  0.482 1 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
WIN3  TCC  0.182  0.000  0.210  0.834  0.843 1 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
WIN3  AAC  1.249  0.025  1.837  0.068**  0.075 0.928 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
WIN3  TAC  -0.432  0.007  -0.969  0.334  0.331 1 rs622525|rs2501325|rs7554182  PINK – CCDC19-ZFN  
WIN4  ATA  -0.847  0.004  -0.760  0.449  0.449 1 rs1962142|rs35652124|rs2886162  PINK – CCDC19-ZFN  
WIN4  GTA  0.337  0.004  0.775  0.440  0.456 1 rs1962142|rs35652124|rs2886162  NRF2  
WIN4  GCG  0.606  0.008  1.052  0.295  0.324 1 rs1962142|rs35652124|rs2886162  NRF2  
WIN4  GTG  -0.661  0.014  -1.396  0.165  0.174 1 rs1962142|rs35652124|rs2886162  NRF2  
WIN6  GAG  -2.153  0.007  -1.002  0.318  0.303 1 rs7387720|rs2293925|rs724037  NRF2  
WIN6  GGG  -0.934  0.022  -1.756  0.081**  0.078 0.959 rs7387720|rs2293925|rs724037  TOP1mt  
WIN6  AGG  1.288  0.004  0.767  0.445  0.431 1 rs7387720|rs2293925|rs724037  TOP1mt  
      P-value (Significant)    : *  
      P-value (border line Significant)  : **  
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LOCUS  HAPLOTYPE  Beta  R2  STAT  P-value  pEMP1 pEMP2 SNPS  GENES  
WIN6  AGT  0.801  0.020  1.640  0.103  0.105 0.982 rs7387720|rs2293925|rs724037  TOP1mt  
WIN7  AGC  -1.826  0.007  -0.978  0.330  0.314 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN7  GGC  -0.751  0.016  -1.463  0.146  0.141 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN7  GTC  0.158  0.001  0.304  0.762  0.757 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN7  GTT  0.545  0.011  1.229  0.221  0.212 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN8  GCA  -0.705  0.008  -1.053  0.294  0.287 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TCA  2.068  0.010  1.140  0.257  0.244 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TTA  1.057  0.022  1.716  0.089**  0.096 0.968 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  GCG  -1.289  0.017  -1.516  0.132  0.126 0.997 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TCG  -0.012  0.000  -0.023  0.982  0.976 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TTG  0.002  0.000  0.003  0.997  0.996 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN9  CGT  0.542  0.008  1.022  0.309  0.312 1 rs11006126|rs2306604|rs1049432  TOP1mt  
WIN9  TGT  -2.805  0.017  -1.505  0.135  0.159 0.998 rs11006126|rs2306604|rs1049432  TOP1mt  
WIN9  CAG  0.329  0.000  0.222  0.825  0.846 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  TAG  0.086  0.000  0.135  0.893  0.898 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  CGG  -0.118  0.000  -0.137  0.891  0.889 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  TGG  -0.249  0.002  -0.573  0.567  0.582 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN10  GTG  0.309  0.003  0.588  0.558  0.549 1 rs2306604|rs1049432|rs11006132  TFAM  
WIN10  AGA  0.120  0.000  0.209  0.834  0.853 1 rs2306604|rs1049432|rs11006132  TFAM  
WIN10  GGA  -0.151  0.001  -0.344  0.732  0.733 1 rs2306604|rs1049432|rs11006132  TFAM  
WIN11  TGA  -0.964  0.003  -0.598  0.551  0.575 1 rs1049432|rs11006132|rs17113613  TFAM  
WIN11  GAA  -0.745  0.007  -0.966  0.336  0.346 1 rs1049432|rs11006132|rs17113613  TFAM  
WIN11  TGG  0.474  0.005  0.842  0.402  0.402 1 rs1049432|rs11006132|rs17113613  TFAM-C10orf2  
WIN11  GAG  0.181  0.001  0.388  0.699  0.679 1 rs1049432|rs11006132|rs17113613  TFAM-C10orf2  
WIN12  GAC  -1.358  0.006  -0.865  0.389  0.407 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  AAC  -0.802  0.008  -1.042  0.299  0.313 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  GGC  -0.451  0.001  -0.432  0.666  0.642 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  AGC  0.149  0.000  0.235  0.815  0.799 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
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LOCUS  HAPLOTYPE  Beta  R2  STAT  P-value  pEMP1 pEMP2 SNPs  GENES  
WIN12  GGT  0.631  0.006  0.936  0.351  0.383 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  AGT  0.124  0.001  0.263  0.793  0.799 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN13  ACT  -0.828  0.013  -1.310  0.193  0.197 1 rs17113613|rs3740485|rs3740486  TFAM-C10orf2  
WIN13  GCT  0.057  0.000  0.109  0.914  0.918 1 rs17113613|rs3740485|rs3740486  TFAM-C10orf2  
WIN13  GTC  0.374  0.005  0.795  0.428  0.413 1 rs17113613|rs3740485|rs3740486  C10orf2  
WIN14  CTG  -0.289  0.003  -0.613  0.541  0.533 1 rs3740485|rs3740486|rs11190787  C10orf2  
WIN14  TCT  0.372  0.005  0.791  0.430  0.421 1 rs3740485|rs3740486|rs11190787  C10orf2  
WIN17  TC  0.558  0.007  0.987  0.326  0.337 1 rs9905016|rs2075551  POLG2  
WIN17  CC  1.598  0.009  1.116  0.267  0.227 1 rs9905016|rs2075551  POLG2  
WIN17  CG  -0.741  0.014  -1.372  0.172  0.188 1 rs9905016|rs2075551  POLG2  
      P-value (Significant)    : *  
      P-value (border line Significant)  : **  
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3.9.2 Multivariate analysis of genetic associations with pain intensity  
Multivariate analysis was performed only on SNPs, genotypes and haplotypes 
with P-values < 0.5 during univariate analysis. The multivariate analysis involved 
inclusion of covariates that were significantly associated with SN during analyses 
of demographic data i.e. age and height. These covariates were tested as to 
whether they had any additive effect on pain intensity  
The two SNPs NRF3 (rs4722585) and TOP1mt (rs7387720) associated with pain 
intensity in SN patients in univariate analysis, were further analysed for 
association using the multivariate model (linear regression analysis) and they 
maintained their significance when age and height were also considered (Table 
3.20). The rs4722585 SNP had P = 0.013 for association with an increase in pain, 
and a significant EMP1 of 0.013 was also obtained. TOP1mt SNP rs7387720 was 
border line significant P = 0.054 for association with a decrease in pain intensity 
in SN patients and was also border line significant after correction EMP1 of 
0.054.  However, pEMP2 values were all above 0.05, indicating that these alleles 
were not significantly associated with pain intensity after correction for multiple 
testing. Similarly, genotypes shown in Table 3.21 were not significantly 
associated with pain intensity after correction for multiple testing. 
 
Table 3.20. Linear regression analysis of alleles in association with pain 
intensity including age and height as covariates.  
Gene  SNP  Beta  STAT  P- 
Value  
EMP1  EMP2  Pain 
Intensity  
 NRF3 rs4722585  0.214  2.525  0.013*  0.013*  0.238  ↑  
TOP1mt  rs7387720  -0.166  -1.942  0.054  0.054  0.683  ↓  
P-value (Significant)    : *  
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Table 3.21. Linear regression analysis of genotypes in association with pain intensity.  
Gene  SNP  Genotype 
Model  
BETA  P-value  Bonferroni P-
value  
EMP1  EMP2  Pain 
Intensity  
PINK1  rs10799655  Genotypic   
NA  
0.029* 0.895  0.701  1  -  
PINK1  rs10799655  Dominant  0.213  0.015* 0.658  0.022*  0.296  ↑  
NFE2L3  rs4722585  Genotypic  
NA  0.042*  
1  
0.031*  0.521  
-  
NFE2L3  rs4722585  Dominant  
0.201  0.019*  
0.506  
0.013*  0.346  
↑  
TOP1mt  rs7387720  Genotypic  
NA  0.085  
1  
0.399  1  
-  
TOP1mt  rs7387720  Dominant  
-0.188  0.028*  
0.740  
0.032*  0.473  
↓  
 P-value (Significant)    : *  
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In summary, Table 3.22 below shows all results for association with pain intensity.  
Table 3.22. Summary results of Pain intensity.   
        Univariate analyses   Multivariate analyses  
Gene  SNP  Model  Associated with  P-value  pEMP1  Beta  P-value  pEMP1  pEMP2  Beta  
PINK1  rs10799655  Genotypic   pain intensity  
0,059  0,727  NA  
0.029*  0.701  1  NA  
PINK1  rs10799655  Dominant  pain intensity  
0.029*  0.031*  0.188  
0.015*  0.022*  0.296  0.213  
NRF3  rs4722585  Allelic  pain intensity   0.014*  0.014*  
0.209  
0.012*  0.013*  0.238  0.214.  
NRF3  rs4722585  Genotypic   pain intensity  
0,045*  0,059  NA  0.042*  0.031*  0.521  
NA  
NRF3  rs4722585  Dominant  pain intensity  
0.018*  0.023  0.202  0.019*  0.013*  0.346  
0.201  
TOP1mt  rs7387720  Allelic  pain intensity   0.053  0.05  
-0.166  
0.054  0.054  0.683  -0.166  
TOP1mt  rs7387720  Dominant  pain intensity   
0.030*  0.033*  -0.186  0.028*  0.032*  0.473  
-0.188  
P-value (Significant)    : * 
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3.10   Associations between alleles, genotype, haplotypes and mtDNA copy 
number  
3.10.1 Univariate analysis of associations between genetic variants and 
mtDNA copy number  
When we compared mtDNA copy number to SNP alleles, we found that there was 
no significant association with all variants (Table 3.23). SNPs in blue on the 
Table below had the lowest P-values for association with mtDNA copy number in 
the cohort but all were above significance level of 0.05. When computation for 
multiple correction was done, all SNPs remained insignificant for association with 
mtDNA copy number.  
When we compared genotypes with mtDNA copy number, we found that none of 
the SNPs were significantly associated with mtDNA copy number. All SNPs were 
above significance level of P < 0.05.  
When we compared mtDNA copy number to haplotypes (Table 3.24), we found 
that three haplotypes on chromosome ten (rs11006126| rs2306604| rs1049432 
TGT in TFAM, rs11006132 |rs17113613| rs3740485 GGC across TFAM and 
C10orf2, and rs17113613| rs3740485| rs3740486 GCT in C10orf2) were 
significantly associated with mtDNA copy number in this cohort with P = 0.007, 
0.001 and 0.038 respectively.  They were all associated with increased mtDNA 
copy number as seen by the strongly positive Beta value.  There was no single 
SNP in common between these three haplotypes, but they were all in the TFAM 
and C10orf2 genes on chromosome 1. In addition, another four haplotypes in the 
TFAM-C10orf2 region also showed weak associations with mtDNA copy number 
(P>0.05 but < 0.10). None of the SNPs in these haplotypes were independently 
associated with SN risk or mtDNA copy number in allelic or genotypic models. 
The TFAM haplotype here associated with mtDNA copy number (rs11006126| 
rs2306604| rs1049432 TGT) was different to the TFAM haplotype associated with 
SN (rs11006126|rs2306604|rs1049432 CGG), but had the rs2306604 G in 
common. 
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Table 3.23. Basic association test of alleles with mtDNA copy number.  
Gene  SNP ID  Beta  T-test  
P-value  
  
Bonferroni   
P-value  
  
EMP1  EMP2  
PINK1  
rs10799655  -0.032  0.646  1  0.643  1  
rs650616  -0.020  0.771  
1  
0.770  1  
rs622525  -0.070  0.314  
1  
0.313  1  
CCDC19  
rs2501325  0.068  0.331  
1  
0.332  1  
ZFN648  
rs7554182  -0.090  0.197  
1  
0.197  0.988  
  
NRF2  
rs1962142  0.083  0.236  
1  
0.234  0.996  
rs35652124  0.120  0.085**  
1  
0.085  0.834  
rs2886162  -0.082  0.247  
1  
0.249  0.997  
NFE2L3  
rs4722585  -0.062  0.375  
1  
0.378  1  
  
  
TOP1mt  
rs7387720  0.005  0.942  
1  
0.942  1  
rs2293925  -0.002  0.982  
1  
0.982  1  
rs724037  -0.005  0.947  
1  
0.947  1  
rs11544484  -0.044  0.534  
1  
0.537  1  
rs2450772  0.029  0.684  
1  
0.688  1  
  
  
TFAM  
rs11006126  0.009  0.901  
1  
0.903  1  
rs2306604  -0.052  0.459  
1  
0.461  1  
rs1049432  0.088  0.207  
1  
0.209  0.991  
rs11006132  0.122  0.082**  1  0.083  0.822  
  
C10orf2  
rs17113613  -0.015  0.827  
1  
0.829  1  
rs3740485  0.119  0.091**  1  0.093  0.853  
rs3740486  0.120  0.087**  1  0.088  0.840  
rs11190787  0.132  0.062**  1  0.063  0.730  
POLG  rs2856268  -0.109  0.121  1  0.120  0.926  
LITAF  rs13333308  -0.123  0.077**  1  0.075  0.804  
POLG2  
 
 
rs9905016  -0.085  0.228  
1  
0.228  0.995  
rs2075551  -0.078  0.265  
1  
0.264  0.998  
P-value (Significant)  : *  
P-value (Border-line Significant) : **   
  
108 
 
Table 3.24. Haplotype association with mtDNA copy number.   
LOCUS  HAPLOTYPE  Beta  R2  STAT  P  pEMP1  pEMP2 SNPS  GENES  
WIN1  TGA  -17.27  0.0032  -0.81  0.418  0.414 1 rs10799655|rs650616|rs622525  PINK1  
WIN1  CAT  -5.33  0.0005  -0.33  0.745  0.754 1 rs10799655|rs650616|rs622525  PINK1  
WIN1  TGT  6.994  0.0004  0.29  0.771  0.795 1 rs10799655|rs650616|rs622525  PINK1  
WIN1  CGT  17.46  0.0047  0.99  0.325  0.330 1 rs10799655|rs650616|rs622525  PINK1  
WIN2  GAC  89.9  0.0044  0.95  0.344  0.301 1 rs650616|rs622525|rs2501325  PINK1 – CCDC19  
WIN2  ATC  1.683  8.3e-006  0.04  0.967  0.973 1 rs650616|rs622525|rs2501325  PINK1 – CCDC19  
WIN2  GTC  29.74  0.005  1.02  0.311  0.301 1 rs650616|rs622525|rs2501325  PINK1 – CCDC19  
WIN2  GAA  -27.63  0.008  -1.27  0.207  0.202 1 rs650616|rs622525|rs2501325  PINK1 – CCDC19  
WIN2  ATA  -6.234  0.0006  -0.35  0.724  0.731 1 rs650616|rs622525|rs2501325  PINK1 – CCDC19  
WIN2  GTA  10.38  0.002  0.58  0.563  0.572 1 rs650616|rs622525|rs2501325  PINK1 – CCDC19  
WIN3  ACT  77.11  0.004  0.88  0.382  0.349 1 rs622525|rs2501325|rs7554182  PINK1 – CCDC19-ZFN  
WIN3  TCT  -5.952  4.1e-005  -0.09  0.927  0.931 1 rs622525|rs2501325|rs7554182  PINK1 – CCDC19-ZFN  
WIN3  AAT  -57.75  0.005  -0.96  0.336  0.335 1 rs622525|rs2501325|rs7554182  PINK1 – CCDC19-ZFN  
WIN3  TAT  -30.19  0.009  -1.37  0.171  0.167 1 rs622525|rs2501325|rs7554182  PINK1 – CCDC19-ZFN  
WIN3  TCC  26.53  0.005  0.99  0.322  0.325 1 rs622525|rs2501325|rs7554182  PINK1 – CCDC19-ZFN  
WIN3  AAC  -26.47  0.005  -1.05  0.294  0.296 1 rs622525|rs2501325|rs7554182  PINK1 – CCDC19-ZFN  
WIN3  TAC  19.33  0.007  1.20  0.232  0.214 1 rs622525|rs2501325|rs7554182  NRF2  
WIN4  ATA  25.65  0.002  0.62  0.536  0.569 1 rs1962142|rs35652124|rs2886162  NRF2  
WIN4  GTA  -25.28  0.011  -1.52  0.130  0.134 0.996 rs1962142|rs35652124|rs2886162  NRF2  
WIN4  GCG  32.74  0.012  1.60  0.111  0.126 0.993 rs1962142|rs35652124|rs2886162  NRF2  
WIN4  GTG  -5.826  0.001  -0.35  0.728  0.731 1 rs1962142|rs35652124|rs2886162  TOP1mt  
WIN6  GAG  14.77  0.0002  0.18  0.855  0.844 1 rs7387720|rs2293925|rs724037  TOP1mt  
WIN6  GGG  0.9037  1.1e-005  0.05  0.963  
0.964 1 
rs7387720|rs2293925|rs724037  TOP1mt  
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LOCUS  HAPLOTYPE  Beta  R2  STAT  P  pEMP1  pEMP2 SNPS  GENES  
WIN6  AGG  -54.47  0.0043  -0.94  0.349  0.369 1 rs7387720|rs2293925|rs724037  TOP1mt  
WIN6  GGT  10.28  9.9e-005  0.14  0.887  0.868 1 rs7387720|rs2293925|rs724037  TOP1mt  
WIN6  AGT  3.75  0.0002  0.21  0.832  0.832 1 rs7387720|rs2293925|rs724037  TOP1mt  
WIN7  AGC  -1.689  2.6e-006  -0.02  0.982  0.977 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN7  GGC  -2.386  7.9e-005  -0.13  0.899  0.906 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN7  GTC  -12.03  0.002  -0.64  0.521  0.529 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN7  GTT  10.04  0.002  0.65  0.520  0.508 1 rs2293925|rs724037|rs11544484  TOP1mt  
WIN8  GCA  -1.012  9.61e-006  -0.04  0.965  0.960 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TCA  81.97  0.005  1.03  0.305  0.287 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TTA  5.905  0.0004  0.28  0.778  0.776 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  GCG  -5.906  0.0002  -0.18  0.857  0.851 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TCG  -17.51  0.004  -0.90  0.370  0.399 1 rs724037|rs11544484|rs2450772  TOP1mt  
WIN8  TTG  8.299  0.001  0.47  0.636  0.670 1 rs724037|rs11544484|rs2450772  TFAM  
WIN9  CGT  10.82  0.002  0.58  0.564  0.577 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  TGT  197  0.036  2.75  0.007*  0.014* 0.345 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  CAG  -42.99  0.007  -1.17  0.245  0.228 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  TAG  -3.122  8.6e-005  -0.13  0.895  0.889 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  CGG  12.02  0.0005  0.31  0.754  0.769 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN9  TGG  -9.996  0.002  -0.62  0.533  0.531 1 rs11006126|rs2306604|rs1049432  TFAM  
WIN10  GTG  23.51  0.008  1.27  0.207  0.219 1 rs2306604|rs1049432|rs11006132  TFAM  
WIN10  AGA  -14.77  0.003  -0.74  0.461  0.483 1 rs2306604|rs1049432|rs11006132  TFAM  
WIN10  GGA  -14.9  0.00  -0.93  0.354  0.366 1 rs2306604|rs1049432|rs11006132  TFAM-C10orf2  
WIN11  TGA  -27.87  0.0009  -0.44  0.662  0.660 1 rs1049432|rs11006132|rs17113613  TFAM-C10orf2  
WIN11  GAA  -1.374  1.0e-005  -0.05  0.963  0.961 1 rs1049432|rs11006132|rs17113613  TFAM-C10orf2  
WIN11  TGG  29.07  0.011  1.48  0.140  0.152 0.998 rs1049432|rs11006132|rs17113613  TFAM-C10orf2  
110 
 
LOCUS  HAPLOTYPE  Beta  R2  STAT  P  pEMP1  pEMP2 SNPS  GENES  
WIN11  GAG  -26.23  0.012  -1.57  0.118  0.128 0.994 rs1049432|rs11006132|rs17113613  TFAM-C10orf2  
WIN12  GAC  -31.42  0.001  -0.50  0.618  0.625 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  AAC  -1.418  1.2e-005  -0.05  0.961  0.963 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  GGC  116  0.054  3.42  0.001*  0.004* 0.098 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  AGC  11.52  0.001  0.53  0.598  0.613 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  GGT  4.211  0.0002  0.18  0.860  0.875 1 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN12  AGT  -31.76  0.018  -1.95  0.053** 0.053** 0.908 rs11006132|rs17113613|rs3740485  TFAM-C10orf2  
WIN13  ACT  -5.575  0.0003  -0.23  0.816  0.818 1 rs17113613|rs3740485|rs3740486  C10orf2  
WIN13  GCT  37.45  0.021  2.09  0.038*  0.051** 0.826 rs17113613|rs3740485|rs3740486  C10orf2  
WIN13  GTC  -28.01  0.015  -1.74  0.084**  0.105 0.976 rs17113613|rs3740485|rs3740486  C10orf2  
WIN14  CTG  30.03  0.017  1.85  0.066**  0.074** 0.946 rs3740485|rs3740486|rs11190787  C10orf2  
WIN14  TCT  -28.01  0.015  -1.74  0.084**  0.105 0.976 rs3740485|rs3740486|rs11190787  C10orf2  
WIN17  TC  -24.09  0.007  -1.21  0.228  0.233 1 rs9905016|rs2075551  POLG2  
WIN17  CC  8.208  0.0002  0.20  0.845  0.853 1 rs9905016|rs2075551  POLG2  
WIN17  CG  19.96  0.005  1.06  0.292  0.305 1 rs9905016|rs2075551  POLG2  
P-value (Significant)  : * 
P-value (Border-line Significant)           :**
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3.10.2 Multivariate analysis of genetic variants vs mtDNA copy number  
No multivariate analysis was conducted on mtDNA copy number since no demographic data 
was significantly associated with mtDNA copy number.   
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In summary, Table 3.25 below shows all results for association with mtDNA copy number.   
Table 3.25: Summary of genetic variants vs mtDNA copy number.  
Gene SNP Model Associated with Univariate analyses   
Beta P-value  pEMP1  pEMP2 
TFAM  rs11006126|rs2306604|rs1049432  Haplotype  
(TGT)  
mtDNA copy number  
0.007*  
0.015*  0.345 197  
TFAM-c10orf2 
(chr10)  
rs11006132|rs17113613|rs3740485  Haplotype  
(GGC)  
mtDNA copy number  
0.001*  0.003*  0.098 
116  
TFAM-c10orf2 
(chr10)  
rs11006132|rs17113613|rs3740485  Haplotype  
(AGT)  
mtDNA copy number  0.053  0.054  0.908 -31.76  
C10orf2  rs17113613|rs3740485|rs3740486  Haplotype  
(GCT)  
mtDNA copy number  0.038*  0.051  0.826 37.45  
P-value (Significant)  : * 
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3.11 Genetic risk scores (GRS)    
GRS was performed using the SNPs that were found to be significantly associated 
with SN, pain intensity and mtDNA copy number. GraphPad Prism v7.0 was used 
for statistical analysis of both categorical and continuous data.  
3.11.1 GRS and SN  
The risk alleles of SNPs found to be associated with SN during univariate analysis 
were used to compute GRS. Only rs1962142, rs724037 and rs2856268 SNPs from 
NRF2, TOP1mt and POLG1 genes, respectively, were found to be significantly 
associated with SN. Majority of the patients in our study cohort did not carry the 
risk alleles of both SNPs since they had a GRS of 0. Figure 3.9 below shows the 
association between GRS from 3 SNPs and SN. A P-value of 0.583 was obtained.  
Therefore, these three SNPs do not cumulatively contribute to SN.  
  
Figure 3.9. GRS vs SN. GRS 0 = absence of risk allele, GRS 1 = presence of one 
risk allele, GRS 2 = presence of two risk alleles, GRS 3 = presence of three risk 
alleles  
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3.11.2 GRS and pain intensity  
SNPs rs4722585 (NRF2) and rs7387720 (TOP1mt) were significantly associated 
with pain intensity during univariate analysis. The rs10799655 SNP in PINK1 
gene was borderline significant after correction for pEMP1. Risk alleles from all 
three SNPs were used for calculation of GRS. With the aid of GraphPad prism 
v7.0, an unpaired and non-parametric T-test (Mann-Whitney test), a P-value of 
0.940 (Figure 3.10) was computed and it was statistically not significant for 
association with pain intensity. Therefore, these three SNPs do not cumulatively 
contribute to pain intensity in SN. 
 
  
Figure 3.10: GRS vs pain intensity in patients with SN. GRS 0 = absence of risk 
allele, GRS 1 = presence of one risk allele, GRS 2 = presence of two risk alleles, 
GRS 3 = presence of three risk alleles, GRS 4 = presence of four risk alleles and 
GRS 5 = presence of five risk alleles.   
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3.11.3 GRS and mtDNA copy number  
Since no SNP was significantly associated with mtDNA copy number during 
univariate analysis, the risk alleles of SNPs which were found to be borderline 
significant (P > 0.05 but < 0.1) were used for the calculation of the GRS.  
Three SNPs (rs3740485, rs3740486 and rs11190787) from the C10orf2 gene, one 
SNP (rs11006132) from the TFAM gene and one SNP (rs35652124) from the 
NRF2 gene were all borderline significant for association with mtDNA copy 
number in HIV-positive patients exposed to d4T. Once GRS computation was 
complete, one-way ANOVA was employed for computation of P-value. A non-
significant P-value was generated (P = 0.378) as depicted by Figure 3.11. 
Therefore these four SNPs do not cumulatively contribute to mtDNA copy 
number variation. 
  
Figure 3.11: GRS vs mtDNA copy number in HIV-positive patients exposed to 
d4T. GRS 2 = presence of two risk alleles, GRS 3 = presence of three risk alleles, 
GRS 4 = presence of four risk alleles, GRS 5 = presence of five risk alleles, GRS 6 
= presence of six risk alleles and GRS 7 = presence of seven risk alleles. 
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CHAPTER 4: DISCUSSION AND 
CONCLUSION  
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SN is a common neurological side effect related to use of d4T-containing ART. 
Signs and symptoms include a sense of pins-and-needles, loss/reduced reflexes of 
ankles and sense of vibration. SN is thought to arise via ART inhibition of 
mtDNA polymerase gamma, with subsequent effects on mtDNA copy number and 
mitochondrial function. The fact that not everyone using d4T experiences SN 
suggests a possible genetic predisposition underlying SN occurrence.  
Genetic variation in POLG (Chiappini et al. 2009) and the TNFa region (Cherry et 
al. 2008; Wadley et al. 2014) has previously been shown to associate with SN 
after ART use. However, it has also been shown that genetic variation in the 
POLG gene is not an underlying cause of SN after ART use in African 
populations (van Oosterhout et al. 2013; Ojwach et al., 2016).  The role of 
variation in other genes influencing mtDNA replication in SN development after 
ART has not been explored much, although variation in these genes were not 
found to be associated with SN in the GWAS performed by Leger et al. (2014).   
Variation in most of these genes has not previously been described in Black South 
Africans. The first aim of this study was therefore to determine whether genetic 
variation in candidate nuclear genes influencing mitochondrial replication was 
associated with the development of SN in Black South African HIV-positive 
individuals who have used d4T containing antiretroviral therapy.  
There has been conflicting information in the literature regarding the occurrence 
of decreased mtDNA copy number in individuals experiencing SN after ART use.  
A decrease in mtDNA copy number has been demonstrated in nerve cells in 
patients with SN after ART (Dalakas et al. 2011), in whole blood samples from 
Malawian patients with SN on d4T ART (Kampira et al.  2014). and in association 
with other phenotypes of mitochondrial toxicity after ART use, including 
lipodystrophy (Chiappini et al. 2009) and lactic acidosis (Cote et al. 2002; 
Kampira et al. 2014). However Cherry et al. (2002) showed that ART-induced 
lactatemia was associated with decreased mtDNA copy number in adipose tissue 
but not in PBMC. The second aim of this study was therefore to check if mtDNA 
copy number was decreased in whole blood from South African individuals who 
experienced SN after d4T use.  Thirdly, the associations between SNPs in the 
118  
  
genes governing mtDNA replication and variation in mtDNA copy number were 
examined.  
We examined associations between 28 SNPs from 11 genes (POLG, POLG2, 
NRF2, TFAM, C10orf2, TOP1mt, PINK1, NRF3, LITAF, CCDC19 and ZNF648) 
genes and three different phenotypes: SN, pain intensity and mtDNA copy 
number. These SNPs were chosen based on their reported or predicted functional 
effect, effect on mtDNA copy number, and/or association with SN.  It was also 
taken into consideration whether the SNPs had MAF greater or equals to 5% in 
LWK, if SNP assay could be designed successfully in Sequenom software, and 
whether they were tag SNPs.  Four of the SNPs were chosen due to their very low 
(although not genome-wide) significance levels in Africans with SN in the GWAS 
performed by Leger et al. (2014). The associations between these SNPs and 3 
phenotypes (SN, mtDNA copy number and pain intensity), were assessed in a 
black South African cohort on d4T-ART for at least six months.   
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4.1 Genetic variation in nuclear genes of the mtDNA replication pathway in 
the black SA population   
 
Our reports of MAF for these SNPs in the black South African populations is 
novel.  The MAF for 25 of the SNPs was >5% in the cohort of Black South 
Africans. Our findings showed that all 26 SNPs were in Hardy-Weinberg 
equilibrium (HWE) and there was a slight variation in frequencies of the alleles 
when compared to the LWK and YRI African populations.    
Our data were used to construct haplotypes in six genes: POLG2, NRF2, C10orf2, 
TOP1mt, TFAM, PINK1. In addition, haplotypes across three genes on 
chromosome 1 (PINK, ZNF648 and CCDC19) and across two genes on 
chromosome 10 (TFAM and c10orf2) were constructed. Shorter haplotypes were 
expected in African populations as compared to non-African populations. 
Variation in allele frequencies and LD estimates in different populations may be 
due to micro-evolutionary factors, such as genetic drift, migration, population 
structure and natural selection.   
4.2 Association of demographic factors with SN and with mtDNA copy number   
Demographic variables of age and height were found to be major risk factors for 
SN in HIV-positive patients treated with d4T-containing regimens This was 
previously reported in this cohort by Wadley et al., (2011) and Hendry (2015). 
and these associations were similar to results found by Cherry et al., (2009). 
Interestingly length of time on d4T was not significantly associated with SN in 
this cohort, which could indicate that d4T mediates toxicity within a short time 
period. Menezes et al., (2013) reported that patients who were exposed to the 
standard and low dose d4T had a decrease in mean mtDNA copy number/cell of 
29 % and 32 %, respectively when compared with TDF after only four weeks.  
Kampira (2013) found that body mass index (BMI) and age (> 40) were 
significantly associated with d4T associated adverse effects and the possible 
mechanism was thought to be via increased ROS due to the synergistic effect of 
both NRTIs and age.  
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4.3 Genetic associations with SN after d4T use   
We found three SNPs and two haplotypes that were significantly associated with 
the occurrence of SN in our cohort using univariate analysis. These included 
rs1962142 in NRF2, rs724037 in TOP1mt and rs2856268 in POLG and haplotypes 
rs7387720|rs2293925|rs724037 GGT in TOP1mt and TFAM 
rs11006126|rs2306604|rs1049432 CGG. All of these represent novel loci for 
associations with SN. Of these, (rs7387720|rs2293925|rs724037 GGT in TOP1mt 
and TFAM rs11006126|rs2306604|rs1049432 CGG) remained associated with SN 
in multivariate analysis using age and height as covariates, and may therefore be 
considered as potential independent susceptibility factors for SN occurrence after 
d4T use.   
 
 However, none of these genetic variants remained significant after corrections for 
multiple testing. These results are concordant with the data from Leger et al. (2014) 
who showed that susceptibility to d4T/ddI-associated neuropathy was 
not explained by a single genetic variant with a marked effect.  As seen in GRS, the 
combination of the individual risk alleles of SNPs rs1962142, rs723047 and 
rs2856268 in genes NRF2, TOP1mt and POLG, respectively did not additively 
contribute to SN occurrence. 
 
No significant associations were found between individual SNPs in POLG2, 
C10orf2, TFAM or PINK1, and SN after d4T use. The four SNPs replicated in this 
cohort from GWAS by Leger were not significantly associated with SN in this 
cohort. SN replication studies are important, since they can confirm whether 
certain genetic variants are really associated/not associated with certain clinical 
phenotypes, more importantly in cohorts of different ethnicity.  
 
 The rs1962142 SNP in the NRF2 gene was protective against SN in our study in 
univariate analysis, and a dominant model of genotypic effect was supported. This 
association was not significant when covariates of age and height were taken into 
account using logistic regression or when corrections were made for multiple 
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testing. These results are contradictory to results in the literature that this SNP was 
associated with occurrence of SN in diabetes patients (Xu et al., 2015; Wang et al., 
2015).  Elsewhere in Finnish and Chinese (Han) populations NRF2 SNP rs1962142 
has been associated with low synthesis of NRF2 protein in breast cancer 
(Hartikainen et al., 2012). Low NRF2 expression could potentially cause decreased 
antioxidants and therefore increased mitochondrial damage which may relate to 
mitochondrial toxicity seen in disorders such as SN and breast cancer. This 
mechanism could perhaps underlie any association between rs1962142 SNP and 
neuropathy, but would not explain associations between NRF2 rs1962142 and lack 
of neuropathy seen in this study. In addition, the effects of the SNP on NRF2 
expression in non-cancer patients has not been established.   
 
The rs2856268 SNP in the POLG gene was associated with the development of 
SN in this study in univariate analysis and in a dominant model of genotypic 
effect. This association was not significant when covariates of age and height were 
taken into account using logistic regression or when corrections were made for 
multiple testing. This adds to suggestions by Van Oosterhout et al. (2013) and 
Ojwach et al. (2016) that SNPs in POLG may not be common pathogenic 
determinants of d4T-associated mitochondrial toxicity in African populations. The 
R964C and E1143G POLG gene SNPs were found to be absent in Zulu speaking 
HIV-positive patients exposed to d4T containing ART (Ojwach et al., 2016). 
Ojwach et al., (2016) also found that the POLG SNPs associated with 
Hyperlactatemia, Lactic Acidosis, Lipodystrophy, Peripheral Neuropathy in 
American, Europeans and Asians were absent in their Zulu cohort. In Van 
Oosterhout et al. (2013) neither the R964C nor E1143G SNPs of POLG were 
present among HIV-positive patients from Malawi exposed to d4T containing 
ART. In addition, when Van Oosterhout et al. (2013) sequenced the entire POLG 
gene in ten Malawian patients with severe d4T side effects, they found no 
mutations.   
 
The lack of association in the current study between rs2856268 in POLG and SN 
in multivariate analysis, is different to observations that this SNP was associated 
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with the development of diabetic polyneuropathy in Russian patients diagnosed 
with type 1 diabetes mellitus (Spitsina et al. 2009; Malyarchuk et al., 2011). The 
rs2856268 SNP is located in the 5’- promoter region of the POLG gene. The 
patients with diabetic neuropathy harbouring the rs2856268 SNP C allele had a 
decreased synthesis of the POLG enzyme as compared to the control group 
(Spitsina et al., 2009). In the current study the SNP was not associated with 
decreased mtDNA copy number; we did not measure direct effect of the SNP on 
POLG expression or activity.  
  
One SNP rs724037 (allele G) within the TOP1mt gene was found to be 
significantly associated with the development of SN in our cohort but only in 
univariate analysis in an allelic model. This association was not significant when 
covariates of age and height were taken into account using logistic regression or 
when corrections were made for multiple testing. This SNP was therefore not 
considered as independent risk factor for SN occurrence after d4T use. No 
associations between rs724037 (allele G) and any type of neuropathy has been 
previously reported.   
The TOP1mt haplotype (GGT rs7387720|rs2293925|rs724037) was significantly 
associated with protection against SN in our cohort in both univariate and 
multivariate analysis. This protective haplotype included rs724037 allele T, which 
is consistent with the association of rs724037 (risk allele G) with SN discussed 
above. The rs7387720 SNP within the protective TOP1mt haplotype, has 
previously been associated with SN in Diabetes mellitus type 1 patients from 
Russia (Swan et al., 2015), consistent with association with SN in this study. This 
SNP   rs7387720 (allele G), was also significantly associated with pain intensity in 
both univariate and multivariate analysis in this study. Both rs724037 (allele G 
SNP) and rs7387720 have previously been associated with diabetic kidney disease 
and end-stage renal disease in Caucasian Europeans (Swan et al., 2015). How the 
rs724037 SNP, an intron variant, causes dysfunction of the topoisomerase enzyme 
is not known. Wang et al. (2011) found that the minor allele of the TOP1mt 
rs2293925 SNP was associated with TOP1mt protein truncation in patients 
diagnosed with mitochondrial disorders. 
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Lastly, the CGG haplotype from the TFAM (Mitochondrial transcription factor A) 
gene was associated with the development of SN in the current study in univariate 
and multivariate analyses. The haplotype was constructed with alleles from the 
following TFAM gene SNPs, rs11006126 C, rs2306604 G and rs1049432 G. The 
rs11006126 SNP was not individually associated with SN development in this 
cohort, but was present in TFAM haplotypes significantly associated with mtDNA 
copy number in this cohort (discussed later). The minor allele C was also 
associated with decreased mtDNA copy number amount in Chinese patients 
diagnosed with depression (Cai et al., 2015), but has not previously been 
associated with any neuropathy.  The single SNP rs2306604 (allele A) located in 
intron 4 of the TFAM gene was associated with the risk of developing Parkinson’s 
Disease (PD) in French patients (Bertram et al., 2007; Laumet et al., 2010) and 
also in British and Scandinavian cohorts (Gatt et al., 2013). Belin et al., (2007) 
showed that rs2306604 A was associated with an increased risk of PD and 
Alzheimer’s disease (AD) development, using case control data from Italy, 
Germany and Switzerland. Similarly, rs1049432 (allele T) was associated with PD 
and AD (Taherzadeh-Fard et al., 2011).   
None of the SNPs and haplotypes described above confer their protective or 
susceptibility effects against SN development after d4T use, by changes in 
mtDNA copy number, as none of them were significantly associated with mtDNA 
copy number in this cohort.    
4.4 Genetic associations with pain intensity after d4T use  
Individual SNPs in NRF3, TOP1mt and PINK1 genes were significantly 
associated with pain intensity in allelic and/or genotypic models in univariate 
analyses. The NRF3 SNP remained significantly associated with pain intensity in 
multivariate analysis. However, none of these genetic variants remained 
significant after corrections for multiple testing.  Risk alleles from rs4722585 
(NRF3), rs7387720 (TOP1mt) and rs10799655 (PINK1) were used for the 
computation of GRS. There was a no significant association of the scores with 
pain intensity, suggesting no additive effect for these risk alleles.   
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The rs4722585 SNP in NRF3 gene was significantly associated with an increase in 
pain intensity in our cohort of HIV-positive patients diagnosed with SN and 
exposed to d4T. In a GWAS by Leger et al., (2014) this SNP was found to be non-
significant for association with SN at genome-wide level, but had a very low P-
value (P = 4.4 x 10-06) in Black individuals, in association with grade 2 SN, where 
grade 2 was defined as sensory alteration or paraesthesia causing greater than 
minimal interference with usual social and functional activities. How the NFR3 
SNP exerts its effect is currently unknown since it is a variant located in the 
regulatory region of the gene and not much literature on this variant is currently 
available. NRF3 gene like NRF2 encodes a transcription factor that regulates the 
synthesis of antioxidants which maintains the normal physiological function of the 
mitochondrial. Any deleterious impairment of this pathway more specifically in 
the neurons can induce pain via starvation of the nerve cells due to low ATP 
production as a result of oxidants damaging the mitochondria (Taherzadeh-Fard et 
al., 2011). If the rs4722585 causes a reduction in the synthesis of NRF3 protein, 
this might decrease antioxidant response and increase ROS damage, therefore 
influencing pain occurrence and intensity.   
TOP1mt SNP rs7387720 was significantly associated with decreased pain 
intensity in HIV-positive patients with SN in our cohort.  It was also associated 
with SN occurrence in our cohort and this SNP was also discussed in the section 
above. The genetic variant was associated with end stage renal disease in patients 
with DM1 (Swan et al., 2015). TOP1mt does not primarily regulate any known 
pain mechanism.   
SNP rs10799655 in the PINK1 gene was significantly associated with pain 
intensity in a dominant model in univariate analysis in our cohort. In a study by 
Franks et al. (2008) the rs10799655 was associated with an increase in PINK1 
mRNA levels in Danish diabetics. PINK1 protein maintains the normal 
physiological function of the mitochondria, and faulty mitochondria are targeted 
by PINK1 for destruction.      
125  
  
4.5 mtDNA copy number association with SN   
mtDNA copy number has been used as a biomarker for many HIV and ART-
related neurological complications including SN (Côté et al., 2002; Cherry et al., 
2002; Kampira et al., 2014). Dalakas et al., (2001) showed that mtDNA copy 
number was depleted in nerve cells during ART- induced SN. While the gold 
standard for the diagnosis of ART - related mitochondrial toxic effects is muscle, 
fat or liver biopsy, this is not practical for routine screening and monitoring (Côté 
et al., 2002).  Kampira et al., (2014) found significantly lowered mtDNA copy 
number in whole blood samples in association with ART- induced SN and 
lactatemia, but not lipodystrophy. It remains debatable whether ART -induced SN 
or other mitochondrial toxicities are associated with mtDNA depletion that can be 
observed in blood cells. 
In the current study, there were no significant differences in mtDNA copy number 
in whole blood samples from South African patients with or without SN after d4T 
use.  The diagnosis of SN in this study differed from the one in Kampira et al., 
(2014), which might be the reason for the contradicting results. Diagnosis of SN in 
Kampira et al., (2014) was based on characteristic symptoms that had started after 
the initiation of ART, while in our study some patients already had SN before ART.  
Cherry et al., (2002) showed that ART-induced lactatemia was associated with 
decreased mtDNA copy number in adipose tissue but not in PBMC. Results 
obtained in the current study were similar to those by Cherry et al., (2002) Urata et 
al., (2008) observed that mtDNA copy number in PBMCs varied due to platelet 
contamination and this caused overestimation of mtDNA content.  Therefore, 
measurement of mtDNA copy number in whole blood samples may not be as 
accurate as measurement in PBMC depleted of platelets.  
    
4.6 Genetic associations with mtDNA copy number after d4T use  
Although our data did not support a decrease in mtDNA copy number in SN, we 
did find significant associations between genetic variants and mtDNA copy 
number in the total cohort. There were no individual alleles or genotypes 
associated with mtDNA copy number in the cohort. Combinations of alleles in 
GRS also did not yield any significant association with mtDNA copy number.   
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Three haplotypes in the TFAM-c10orf2 region on chromosome ten were 
significantly associated with increased mtDNA copy number including TFAM 
haplotype TGT (rs11006126, rs2306604, rs1049432; TFAM-c10orf2 haplotype 
GGC (rs11006132, rs17113613, rs3740485); and C10orf 2 haplotype GCT 
(rs17113613, rs3740485, rs3740486). Since no demographic data were associated 
with mtDNA copy number, no multivariate analyses were performed with these 
haplotypes. 
Two of these haplotypes had C10orf2 rs17113613 (allele G) and C10orf2 
rs3740485 (allele C) in common, strengthening the hypothesis that these variants 
relate to increased mtDNA copy number.  However, these SNPs were not 
individually associated with mtDNA copy number, suggesting that there may be a 
functional underlying SNP in LD with these haplotypes that was not assessed in 
this study.  
One of our haplotypes consisted of SNPs only in the TFAM gene. This 
rs11006126| rs2306604| rs1049432 TGT in TFAM was significantly associated 
with an increase in mtDNA copy number in our cohort. Similarly, the TFAM 
rs11006126 locus has also been highly significantly associated with mtDNA copy 
number in Chinese and UK cohorts (Cai et al., 2015). The rs2306604 risk (allele 
A) has been associated with mtDNA depletion in neurodegenerative disorders 
such as Alzheimer’s, Parkinson’s and Huntington’s disease (Belin et al.,2007; 
Gatt et al., 2013; Taherzadeh-Fard et al., 2011).  This is consistent with our 
finding that the rs2306604 (allele G) (in haplotype) was associated with increased 
amounts of mtDNA. The risk (allele rs1049432 T was found to be associated with 
mitochondrial dysfunction and age of early onset in patients diagnosed with 
Huntington’s disease (Taherzadeh-Fard et al., 2011). Our findings of higher 
mtDNA copy number in association with a haplotype containing this T allele are 
in contrast to their findings of mitochondrial dysfunction in association with this 
allele. Taherzadeh-Fard et al. (2011)  also showed that SNPs rs11006126 and 
rs1049432 were in high LD with each  other in their German cohort,  similar to the 
high LD observed across these SNPs in our African cohort.   
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The haplotype (rs17113613| rs3740485| rs3740486) GCT in C10orf2, and the 
related haplotype (rs11006132 |rs17113613| rs3740485) GGC across TFAM and 
C10orf2, were associated with an elevation in mtDNA in our cohort samples. The 
rs17113613 A has previously been reported in a patient with symptoms of mtDNA 
stability defects (Naimi et al., 2006).  This is consistent with our association of the 
G allele with increased mtDNA. However, the risk alleles of rs3740485 C and 
rs3740486 T SNPs in C10orf2 were associated with Progressive External 
Opthalmoplegia (PEO) in an Indian cohort (Singh et al., 2012). These results are 
in contrast with our results which show association with increased mtDNA. In 
addition, TFAM rs11006132-G was associated with Huntington’s disease risk 
Taherzadeh-Fard et al., 2011) which may indicate association with lower mtDNA 
copy number, again in contrast with our results which show association with 
increased  mtDNA .   
Whilst possession of these three haplotypes was associated with increased mtDNA 
copy number in our cohort, they were not related to susceptibility to or protection 
from ART-induced SN in this cohort. These haplotypes could potentially play a 
role in protection against other ARV/NRTI mitochondrial toxicities, or other 
diseases where mtDNA copy number is important e.g. diabetic neuropathy and 
chemotherapy induced neuropathy 
 4.7 Study limitations  
The cohort size was relatively small (n = 263) for a genetic association study. 
Smaller cohort sizes carry with them lower statistical power for association with 
clinical phenotypes. Similar studies should therefore be reproduced in a larger 
sample.  
When diagnosing SN, patients were not categorised as having SN prior or post 
d4T exposure, this makes it difficult to understand whether HIV or d4T induced 
the SN. Therefore, in future studies, SN diagnosis should occur both before and 
after ART initiation.   
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A different African population (LWK) was used as a proxy to choose SNPs of 
interest. It is possible that the LD in our cohort and that of the proxy population 
differs, which may affect our results especially when using tag SNPs for 
association with respective clinical phenotype. Tag SNPs showing a strong LD in 
LWK may not be when genotyped in South Africans.  This is further proved by 
the fact that many genetic variants that are significantly associated with certain 
disorders in Caucasian populations, become non-significant when replicated in 
African populations (Hendry, 2015).  
 4.8 Future work  
We focussed on 28 SNPs in POLG1, POLG2, NRF2, C10orf2, TOP1mt, TFAM, 
PINK1, CCDC19, LITAF, NRF3and ZNF648 genes in this study.  While no 
genetic variants remained significantly associated with SN or pain intensity after 
correction for multiple testing, our results suggested that variants in the TFAM-
c10orf2 region may influence mtDNA copy number in Black South Africans on 
ART.  It would be interesting to test these results in a larger sample size of healthy 
Black South Africans. Further studies of these loci using increased SNP density 
across the genes may be required (since this will ensure that a larger region of the 
genes of interest is interrogated) and functional studies would also clarify SNP 
role.  Workalemahu et al., (2017) recently published results of GWAS for mtDNA 
copy number and candidate genes arising from their study may be interesting to 
consider in future studies related to mtDNA copy number in Black South 
Africans. 
Overall our findings of several genetic variants that are significantly associated 
with SN and/or mtDNA copy number support other observations in the literature of 
roles for these loci in similar phenotypes. The role of these variants in other 
phenotypes of mitochondrial toxicity apart from SN, such as lactic acidosis or 
lipodystrophy. 
However, the exact role of specific variants in terms of increased or decreased 
mtDNA copy number and susceptibility to SN remains in question, as several of 
our results had the opposite effect to those reported in the literature. It seems 
unlikely that the SNPs would have different effects in different disorders if the 
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disorders all share the common mechanism of mtDNA depletion. However, this 
assumption of common mechanism of mtDNA depletion may not be true, 
especially since several of the articles we were comparing our results to had not 
directly measured mtDNA copy number. Mitochondrial function or damage might 
be more important than mtDNA copy number. Functional mtDNA assays such as 
luciferase assay and lactic acid measurement could be performed since both can 
measure mitochondrial activity and mitochondrial dysfunction respectively.   
Only 28 SNPs in eleven candidate genes were considered here and there are 
obviously vastly many more SNPs and genes that could have been chosen.  For 
example, there are many more genes in the human nuclear genome that play a role 
in mtDNA regulation. There are approximately 1,500 genes that specify nuclear-
encoded mitochondrial proteins some of which are associated with AIDS 
progression (Hendrickson et al., 2010) and which contribute to ART-related 
complications. However, GWAS by Leger et al., (2014) failed to detect any single 
genetic variants that could account for susceptibility to d4T/ddI-associated 
neuropathy, suggesting that it may be unlikely that other mtDNA-related genes 
may be very strongly implicated in SN. 
Sequencing of genes that regulate and/maintain the mitochondria might aid in 
developing SNP database representing genetics of the South African population.  
Inclusion of individuals of varying South African ethnicity would greatly assist in 
the understanding of population stratification and its role in genetic association 
studies. Although the expensive nature of sequencing might serve as a limitation, 
novel polymorphism may also be discovered. All this requires a large cohort size, 
which will improve the statistical power during analysis. The availability of a 
genetic database specifically for South Africans might help when choosing SNPs 
of interest, rather than using a proxy population.  
Since the functional role of some of the genetic variants investigated in the current 
study are unknown, functional studies can also be conducted to help understand 
the impact of these variants. Expression studies of the mitochondrial replisome 
machinery proteins may also aid in understanding as to how mitochondrial 
toxicity due to genetic variants and d4T come about.   
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Even though d4T is no longer in use much in SA, this study remains relevant since 
NRTIs are still being used to treat disorders such as diabetic neuropathy and 
chemotherapy-induced neuropathy. Significant genetic variants in our study could 
be important for other phenotypes related to mtDNA copy number e.g.  AD, PD, 
diabetes, athletic ability and cancer.  
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APPENDIX C  
Gene  
  
SNP  Genotype  Frequency 
in SA  
PINK1 
  
rs10799655  
TT  0.07  
TC  0.45  
CC  0.48  
PINK1   
rs650616  
AA  0.17  
AG  0.5  
GG  0.33  
PINK1   
rs622525  
AA  0.03  
AT  0.3  
TT  0.67  
 CCDC19 
  
rs2501325  
CC  0.03  
CA  0.21  
AA  0.76  
 ZFN648 
  
rs7554182  
TT  0.05  
TC  0.4  
CC  0.54  
 NRF2 
  
rs1962142  
AA  0  
AG  0.13  
GG  0.87  
NRF2   
rs35652124  
CC  0.03  
CT  0.3  
TT  0.67  
NRF2   
rs2886162  
AA  0.18  
AG  0.49  
GG  0.3  
NRF3   
rs4722585  
AA  0.08  
AG  0.35  
GG  0.57  
 
TOP1MT 
  
rs7387720  
GG  0.07  
GA  0.31  
AA  0.63  
 
TOP1MT 
  
rs2293925  
AA  0  
AG  0.02  
GG  0.97  
151  
  
Gene  
  
SNP  Genotype  Frequency 
in SA  
 
TOP1MT 
  
rs724037  
GG  0.07  
GT  0.28  
TT  0.64  
TOP1MT   
rs11544484  
CC  0.19  
CT  0.47  
TT  0.33  
 
TOP1MT 
  
rs2450772  
AA  0.14  
AG  0.5  
GG  0.37  
 TFAM 
  
rs11006126  
CC  0.1  
CT  0.42  
TT  0.48  
TFAM   
rs2306604  
AA  0.04  
AG  0.32  
GG  0.63  
TFAM 
  
rs1049432  
  
TT  0.05  
TG  0.34  
GG  0.6  
TFAM   
rs11006132  
GG  0.06  
GA  0.34  
AA  0.6  
 C10orf2 
  
rs17113613  
AA  0.02  
AG  0.25  
GG  0.73  
C10orf2   
rs3740485  
CC  0.15  
CT  0.47  
TT  0.37  
C10orf2   
rs3740486  
TT  0.15  
TC  0.48  
CC  0.38  
C10orf2   
rs11190787  
GG  0.15  
GT  0.45  
TT  
 
0.38  
152  
  
Gene  
  
SNP  Genotype  Frequency 
in SA  
 POLG 
  
rs2856268  
CC  0.02  
CT  0.24  
TT  0.74  
 LITAF 
  
rs13333308  
CC  0.004  
CT  0.19  
TT  0.81  
 POLG2 
  
rs9905016  
TT  0.04  
TC  0.25  
CC  0.7  
 POLG2 
rs2075551  
  
CC  0.05  
CG  0.3  
GG  0.65  
  
  
